<SEC-DOCUMENT>0001654954-24-012786.txt : 20241008
<SEC-HEADER>0001654954-24-012786.hdr.sgml : 20241008
<ACCEPTANCE-DATETIME>20241008171311
ACCESSION NUMBER:		0001654954-24-012786
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20241008
DATE AS OF CHANGE:		20241008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265995
		FILM NUMBER:		241360930

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>cvm_s3a.htm
<DESCRIPTION>S-3/A
<TEXT>
<html><head><title>cvm_s3a.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Registration No 333-265995&nbsp;</strong></p> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM S-3</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>POST-EFFECTIVE AMENDMENT NO. 1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registration Statement Under</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THE SECURITIES ACT OF 1933</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">CEL-SCI CORPORATION</font></strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in charter)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:40%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Colorado</strong></p></td> <td style="width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&nbsp;84-09l6344</strong></p></td> <td style="width:10%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>8229 Boone Blvd. #802</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Vienna, Virginia 22182</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(703) 506-9460</strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS Employer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">I.D. Number)</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address, including zip code, and telephone number</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">including area of principal executive offices)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:40%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Geert Kersten</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>8229 Boone Blvd. #802</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Vienna, Virginia 22182</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(703) 506-9460</strong></p></td> <td style="width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Name and address, including zip code, and telephone</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">number, including area code, of agent for service)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Copies of all communications, including all communications sent</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">to the agent for service, should be sent to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">William T. Hart, Esq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Hart &amp; Hart</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1624 Washington Street</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Denver, Colorado 80203</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(303) 839-0061</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">From time to time after this Registration Statement</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">becomes effective as determined by market conditions</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&#9746;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&nbsp;&nbsp;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td> <td style="width:20%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="width:30%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accelerated filer</p></td> <td style="width:20%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9744;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Non-accelerated filer</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9746;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Smaller reporting company</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#9746;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant hereby amends this Registration&nbsp;statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall&nbsp;thereafter&nbsp;become effective in accordance with Section 8(a) of the&nbsp;Securities&nbsp;Act of l933 or until the&nbsp;Registration&nbsp;Statement&nbsp;shall become effective on such date as the Commission,&nbsp;acting pursuant to said Section 8(a), may determine.</p> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PROSPECTUS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI Corporation may offer from time to time shares of common stock, preferred stock, convertible preferred stock, rights, warrants, units consisting of one or more of these securities, as well as any of these securities issuable upon conversion of preferred stock or upon the exercise of warrants<strong>,</strong> at an initial offering price not to exceed $150,000,000, at prices and on terms to be determined at or prior to the time of sale in light of market conditions at the time of sale. This prospectus may also be used to reoffer shares held by certain shareholders of CEL-SCI.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Specific terms pertaining to the securities offered by this prospectus will be set forth in one or more accompanying prospectus supplements, together with the terms of the offering and the initial price and the net proceeds to CEL-SCI from the sale. The prospectus supplement will set forth, without limitation, the terms of the offering and sale of such securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI may sell the securities offered by this prospectus directly, through agents designated from time to time, or through underwriters or dealers. If any agents of CEL-SCI or any underwriters or dealers are involved in the sale of the securities, the names of the agents, underwriters or dealers, any applicable commissions and discounts, and the net proceeds to CEL-SCI will be set forth in the applicable prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any selling shareholder may sell the securities offered by this prospectus directly, through agents designated from time to time, or through underwriters or dealers. If any agents of the selling shareholder, or any underwriters or dealers are involved in the sale of the securities, the names of the agents, underwriters or dealer, and any applicable commissions and discounts will be set forth in the applicable prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI may not use this prospectus to complete sales of its securities unless this prospectus is accompanied by a prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The securities offered by this prospectus are speculative and involve a high degree of risk and should be purchased only by persons who can afford to lose their entire investment. For a description of certain important factors that should be considered by prospective investors, see "Risk Factors" on page 10 of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or has passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI's common stock is traded on the NYSE American under the symbol &#8220;CVM&#8221;. On October 3, 2024 the closing price of CEL-SCI&#8217;s common stock on the NYSE American was $1.09.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The date of this Prospectus is ________, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="prospe">PROSPECTUS SUMMARY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>THIS SUMMARY IS QUALIFIED BY THE OTHER INFORMATION APPEARING ELSEWHERE IN THIS PROSPECTUS.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>THE OFFERING</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Securities Offered:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI may offer from time to time shares of common stock, preferred stock,<strong>&nbsp;</strong>convertible preferred stock, rights, warrants, units consisting of one or more of the foregoing securities, as well as any of these securities issuable upon the conversion of preferred stock or upon the exercise of the warrants, at an initial offering price not to exceed $150,000,000, at prices and on terms to be determined at or prior to the time of sale in light of market conditions at the time of sale.&nbsp;&nbsp;Certain shareholders of CEL-SCI may also offer shares issued to them by CEL-SCI.&nbsp; CEL-SCI may not use this prospectus to complete sales of its securities unless this prospectus is accompanied by a prospectus supplement.&nbsp;&nbsp;See the &#8220;Plan of Distribution&#8221; section of this prospectus for additional information concerning the manner in which CEL-SCI&#8217;s securities may be offered.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:20%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common Stock Outstanding:</p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of October 3, 2024 CEL-SCI had&nbsp;63,787,104 outstanding shares of common stock.&nbsp;&nbsp;The number of outstanding shares does not give effect to shares which may be issued upon the exercise and/or conversion of options or warrants.&nbsp;&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Risk Factors:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The purchase of the securities offered by this prospectus involves a high degree of risk.&nbsp;&nbsp;Risk factors include the lack of revenues and history of loss, need for additional capital and need for FDA approval.&nbsp;&nbsp;See the &#8220;Risk Factors" section of this prospectus for additional Risk Factors.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Common Stock</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">NYSE American symbol:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">CVM</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="forward">FORWARD LOOKING STATEMENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 27pt; text-align:justify;">This prospectus and the documents that are incorporated or deemed to be incorporated by reference into this prospectus, contain or incorporate by reference &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continues&#8221; and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceedings;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the success of our clinical studies for our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our expectations regarding federal, state and foreign regulatory requirements;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the therapeutic benefits and effectiveness of our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the safety profile and related adverse events of our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our expectations as to future financial performance, expense levels and liquidity sources;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">anticipated trends and challenges in our potential markets;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to attract, retain and motivate key personnel;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to continue as a going concern; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our liquidity.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 27pt; text-align:justify;">All forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement and the risk factors in the documents incorporated or deemed to be incorporated by reference into this prospectus. The forward-looking statements contained in this prospectus and any document incorporated or deemed to be incorporated by reference in this prospectus, speak only as of their respective dates.&nbsp;&nbsp;Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this prospectus or to<strong>&nbsp;</strong>reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this prospectus and the documents that are incorporated by reference into this prospectus may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="business">BUSINESS OVERVIEW</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this prospectus as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Immunotherapy is a large, high growth market.</u></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A recent Bloomberg report from January 2023 asserted that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (<u>https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</u>)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><u>given first</u></em><u>, right after diagnosis, before any other treatment including surgery</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&nbsp; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&nbsp; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, this accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>What is Multikine and who is it for?</u></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><u>before</u></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET imaging)</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS&lt;10) (via biopsy)</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50). While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, we believe the large majority of patients in this group having low PD-L1 would still be expected to need Multikine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>CEL-SCI believes Multikine leads to longer survival with no safety issues.</u></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong><em><u>risk of death cut in half at five years</u></em></strong><strong><em> </em></strong>versus the control;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), and the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference On Head And Neck Oncology (ECHNO) and the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and 2023 American Head and Neck Society (AHNS). These publications can be accessed at <u>http://www.cel-sci.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Multikine </u></strong><strong><u>works by inducing pre-surgical responses.</u></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine causes pre-surgical responses;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-surgical responses lead to longer life;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><u>none </u></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD. These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg9.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&nbsp; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg10.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Multikine cut the 5-year risk of death in half in the target population.</u></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group, at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg11.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg12.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; (the upper limit of the 95% confidence interval - for the hazard ration - in this case) is still below (better) than the hazard ratio required for most drug approvals. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study.&nbsp; The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms.&nbsp; Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg13.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg14.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.&nbsp; CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, this accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg15.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone. CEL-SCI expects to commence enrollment in Q4 2024/Q1 2025 and reach full enrollment in Q2 2026.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful?</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_s3aimg16.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies, but Multikine can meet the need for improved survival.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has shown to be safe. Every situation is different and depends on the specific facts.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IN CONCLUSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strong survival data</strong>: Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit of 0.66.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Addressing an unmet medical need</strong>: Multikine focuses on the 70% of patients not well served by the two leading approved drugs for head and neck cancer, Keytruda and Opdivo. Multikine&#8217;s proposed indication is a pre-surgical treatment in head &amp; neck cancer, where no drug is currently approved.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Multikine&#8217;s Target Population</strong>: The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>FDA pathway</strong>: CEL-SCI is aiming to begin enrollment for a 212-patient confirmatory registration study in Q4 2024/Q1 2025, with full enrollment expected about Q2 2026. Potential to seek early approval after full enrollment.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>LEAPS</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses &#8220;heteroconjugates&#8221; to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. LEAPS combines T-cell binding ligand peptides with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The ability to generate a specific immune response is important because many diseases are often not combated effectively due to the body&#8217;s selection of the &#8220;inappropriate&#8221; immune response. The capability to specifically reprogram an immune response may offer a more effective approach than existing vaccines and drugs in attacking an underlying disease.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>LEAPS Candidates: CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000)</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On September 19, 2017, CEL-SCI announced that it had been awarded a Phase 2 Small Business Innovation Research (SBIR) grant in the amount of $1.5 million from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which is part of the U.S. National Institutes of Health (NIH). This grant provided funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application for a Phase 1 safety study, by funding IND enabling studies and additional mechanism of action studies, among other preclinical development activities. Work on CEL-4000 was conducted at CEL-SCI&#8217;s research laboratory and Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Jorge O. Galante Professor of Orthopedic Surgery and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery &amp; Biochemistry. The SBIR grant was awarded based on published data described below by Dr. Glant's team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental proteoglycan induced arthritis (PGIA or GIA) when it was administered after the disease was induced in animals. This grant has been fully expended.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As part of the follow-up to the grant funded work, CEL-SCI published a review comparing CEL-4000 and the new LEAPS peptide CEL-5000 to both the Janus kinase (JAK) inhibitors and disease modifying anti-rheumatic drugs (DMARDs) in use for RA and autoimmune arthritis. The article reviewed the mechanism of action and targets with pictorial graphics in the journal Biomedicines and can be found online at <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772713/</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2019, CEL-SCI announced that a newly discovered LEAPS conjugate acts alone and can complement CEL-4000 therapeutically when administered in combination to an animal model of Rheumatoid Arthritis (RA). This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. The data was presented at the American Association of Immunologists 103rd Annual Meeting (Immunology 2019) by Daniel Zimmerman, Ph.D., CEL-SCI&#8217;s Senior Vice President of Research, Cellular Immunology. The work was performed in conjunction with researchers at Rush University Medical Center, Chicago, Illinois and was funded by the SBIR Phase 2 Grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In July 2019, one of CEL-SCI&#8217;s collaborators from Rush, Dr. Adrienn Markovics presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry. Data presented was for a new second RA conjugate discovered which acts alone and can complement the existing CEL-4000 RA vaccine in an animal model of RA. The combination of the two RA conjugates provided not only broader epitope coverage, but also a greater therapeutic effect than either conjugate alone. The LEAPS work was performed in conjunction with researchers at CEL-SCI on CEL-4000 and the newly discovered LEAPS conjugate, CEL-5000. Both conjugates were evaluated alone and in combination in the model of proteoglycan [PG] induced arthritis (PGIA) called recombinant PG G1 domain-induced arthritis (GIA), an autoimmune mouse model of RA.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In February 2017 and November 2016, CEL-SCI announced preclinical data that demonstrate its investigational new drug candidate CEL-4000 has the potential to treat rheumatoid arthritis. This study was supported in part by the SBIR Phase I Grant and was conducted in collaboration with Drs. Katalin Mikecz and Tibor Glant, and their research team at Rush University Medical Center in Chicago, IL. This work was published in an article entitled &#8220;<em>An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis</em>&#8221; and can be found online at <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568759/</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Prior to the SBIR Phase 2 grant in 2014, CEL-SCI was awarded a Phase 1 SBIR grant in the amount of $225,000 from NIAMS. This grant funded the development of CEL-SCI&#8217;s LEAPS technology as a potential treatment for rheumatoid arthritis, an autoimmune disease of the joints. The work was conducted at Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Katalin Mikecz, MD, Ph.D., and Allison Finnegan, Ph.D. Professor of Medicine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">With the support of these SBIR grants, CEL-SCI is developing several new drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid arthritis therapeutic treatments. The data from animal studies using the CEL-2000 treatment suggests that it could be used against rheumatoid arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments currently on the market for arthritic conditions associated with the Th17 signature cytokine TNF-a. The preclinical data indicates these peptides could be used against rheumatoid arthritis where a Th1 signature cytokine (IFN-&#947;) is dominant. CEL-2000 and CEL-4000 each have the potential to become a personalized, disease-specific therapy, that acts at an earlier step in the disease process than current therapies, and which may be useful in patients not responding to existing rheumatoid arthritis therapies. CEL-SCI believes this represents a large unmet medical need in the rheumatoid arthritis market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In March 2015, CEL-SCI and its collaborators published a review article on vaccine therapies for rheumatoid arthritis based in part on work supported by the SBIR Phase 1 grant. The article is entitled &#8220;Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic Ligand Epitope Antigen Presentation System vaccines for models of rheumatoid arthritis&#8221; and was published in Expert Review of Vaccines 1 - 18 and can be found online at <u>http://www.ncbi.nlm.nih.gov/pubmed/25787143</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Accordingly, even though the various LEAPS candidates have not yet been given to humans, they have been tested in vitro with human cells. They have induced similar cytokine responses that were seen in these animal models, which may indicate that the LEAPS technology might translate to humans. The LEAPS candidates have demonstrated protection against lethal herpes simplex virus (HSV1) and H1N1 influenza infection, as a prophylactic or therapeutic agent in animals. They have also shown some level of activity in animals in two autoimmune conditions, curtailing and sometimes preventing disease progression in arthritis and myocarditis animal models.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">None of the LEAPS investigational products have been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from the early-phase, preclinical-trials data involving these investigational products. Before obtaining marketing approval from the FDA in the United States, and by comparable agencies in most foreign countries, these product candidates must undergo rigorous preclinical and clinical testing which is costly and time consuming and subject to unanticipated delays. There can be no assurance that these approvals will be granted.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="risk">RISK FACTORS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Investment in our common stock offered pursuant to this prospectus and any prospectus supplement involves risks. You should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K, and prospectus supplements filed after the date of our most recent annual report on Form 10-K, any such reports we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Securities Exchange Act of 1934, and the risk factors and other information contained in any prospectus supplement and any applicable free writing prospectus before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="uesof">USE OF PROCEEDS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We intend to use the net proceeds from the sale of the securities as set forth in any applicable prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="dilutio">DILUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As of June 30, 2024, we had a net tangible book value of $0.15 per share. An investor purchasing shares pursuant to any prospectus supplement we subsequently file will suffer dilution equal in amount to the difference between the price paid for the securities we offer and our net tangible book value at the time of purchase.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="plan">PLAN OF DISTRIBUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI may sell shares of its common stock, preferred stock, convertible preferred stock, rights, or warrants, units consisting of any of the foregoing, as well as any securities issuable upon the conversion of preferred stock or upon the exercise of warrants in and/or outside the United States: (i) through underwriters, placement agents, or dealers; (ii) directly to a limited number of purchasers or to a single purchaser; or (iii) through agents. The applicable prospectus supplement with respect to the offered securities will set forth the name or names of any underwriters or agents, if any, the purchase price of the offered securities and the proceeds to CEL-SCI from such sale, any delayed delivery arrangements, any underwriting discounts, commissions, and other items constituting underwriters' or placement agents&#8217; compensation, the public offering price and any discounts or concessions allowed or reallowed or paid to dealers and any compensation paid to an underwriter or a placement agent. The public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding the above, the maximum commission or discount to be received by any NASD member or independent broker-dealer will not be greater than 10% in connection with the sale of any securities offered by means of this prospectus or any related prospectus supplement, exclusive of any non-accountable expense allowance. Any securities issued by CEL-SCI to any FINRA member or independent broker-dealer in connection with an offering of CEL-SCI&#8217;s securities will be considered underwriting compensation and may be restricted from sale, transfer, assignment, or hypothecation for a number of months following the effective date of the offering, except to officers or partners (not directors) of any underwriter or member of a selling group and/or their officers or partners.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI&#8217;s securities may be sold:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">At a fixed price.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">As the result of the exercise of warrants or rights, or the conversion of preferred shares, at fixed or varying prices, as determined by the terms of the warrants, rights or convertible securities.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">At varying prices in "at the market" offerings.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In privately negotiated transactions, at fixed prices which may be changed, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">If underwriters are used in the sale, the offered securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale.&nbsp;&nbsp;The securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.&nbsp;&nbsp;The underwriter or underwriters with respect to a particular underwritten offering of securities will be named in the prospectus supplement relating to such offering and, if an underwriting syndicate is used, the managing underwriter or underwriters will be set forth on the cover of such prospectus supplement.&nbsp;&nbsp;Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions precedent and the underwriters may be obligated to purchase all the offered securities if any are purchased.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">If dealers are utilized in the sale of offered securities in respect of which the prospectus<strong>&nbsp;</strong>supplement is delivered, CEL-SCI will sell the offered securities to the dealers as principals.&nbsp;&nbsp;The dealers may then resell the offered securities to the public at varying prices to be determined by the dealers at the time of resale.&nbsp;&nbsp;The names of the dealers and the terms of the transaction will be set forth in the prospectus supplement relating to the securities sold to the dealers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">If an agent is used in an offering, the agent will be named, and the terms of the agency will be set forth, in the prospectus supplement.&nbsp;&nbsp;Unless otherwise indicated in the prospectus supplement, an agent will act on a best efforts basis for the period of its appointment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The securities may be sold directly by CEL-SCI to institutional investors or others, who may be deemed to be underwriters within the meaning of the Securities Act of 1933 with respect to any resale of the securities purchased by the institutional investors.&nbsp;&nbsp;The terms of any of the sales, including the terms of any bidding or auction process, will be described in the applicable prospectus supplement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI may permit agents or underwriters to solicit offers to purchase its securities at the public offering price set forth in a prospectus supplement pursuant to a delayed delivery arrangement providing for payment and delivery on the date stated in the prospectus supplement.&nbsp;&nbsp;Any delayed delivery contract will contain definite fixed price and quantity terms.&nbsp;&nbsp;The obligations of any purchaser pursuant to a delayed delivery contract will not be subject to any market outs or other conditions other than the condition that the delayed delivery contract will not violate applicable law.&nbsp;&nbsp;In the event the securities underlying the delayed delivery contract are sold to underwriters at the time of performance of the delayed delivery contract, those securities will be sold to those underwriters.&nbsp;&nbsp;Each delayed delivery contract shall be subject to CEL-SCI&#8217;s approval.&nbsp;&nbsp;CEL-SCI will pay the commission indicated in the prospectus supplement to underwriters, dealers or agents soliciting purchases of securities pursuant to delayed delivery arrangements accepted by CEL-SCI.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The shares of common stock may be sold by selling shareholders by one or more of the following methods, without limitation:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">at a fixed price;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">at varying prices in &#8220;at the market&#8221; offerings; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">in privately negotiated transactions, at fixed prices which may be changed, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In completing sales, brokers or dealers engaged by the selling shareholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions or discounts from the selling shareholders in amounts to be negotiated. As to any particular broker-dealer, this compensation might be in excess of customary commissions. Neither we nor any selling shareholders can presently estimate the amount of such compensation. Notwithstanding the above, no FINRA member will charge commissions that exceed 8% of the total proceeds from the sale.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The selling shareholders and any broker/dealers who act in connection with the sale of its securities may be deemed to be &#8220;underwriters&#8221; within the meaning of &#167;2(11) of the Securities Acts of 1933, and any commissions received by them and any profit on any resale of the securities as principal might be deemed to be underwriting discounts and commissions under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding the above, while prospectus supplements may provide specific offering terms, or add to or update information contained in this prospectus, any fundamental changes to the offering terms will be made by means of a post-effective amendment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Agents, dealers and underwriters may be entitled under agreements entered into with CEL-SCI to indemnification from CEL-SCI against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments made by such agents, dealers or underwriters.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="descript">DESCRIPTION OF SECURITIES</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><u>Common Stock</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI is authorized to issue 600,000,000 shares of common stock, (the "common stock"). Holders of common stock are each entitled to cast one vote for each share held of record on all matters presented to shareholders. Cumulative voting is not allowed; hence, the holders of a majority of the outstanding shares of our common stock can elect all directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Holders of common stock are entitled to receive such dividends as may be declared by the Board of Directors out of funds legally available therefor and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI's assets after payment of liabilities. The board is not obligated to declare a dividend. It is not anticipated that dividends will be paid in the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Holders of common stock do not have preemptive rights to subscribe to additional shares if issued by CEL-SCI. There is no conversion, redemption, sinking fund or similar provision regarding the common stock. All of the outstanding shares of common stock are fully paid and non-assessable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Preferred Stock</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI is authorized to issue up to 200,000 shares of preferred stock. CEL-SCI's Articles of Incorporation provide that the Board of Directors has the authority to divide the preferred stock into series and, within the limitations provided by Colorado statute, to fix by resolution the voting power, designations, preferences, and relative participation, special rights, and the qualifications, limitations or restrictions of the shares of any series so established. As the Board of Directors has authority to establish the terms of, and to issue, the preferred stock without shareholder approval, the preferred stock could be issued to defend against any attempted takeover of CEL-SCI. Convertible preferred stock is convertible into shares of CEL-CI&#8217;s common stock pursuant to the terms of the convertible preferred shares. As of October 3, 2024, no shares of preferred stock were outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Warrants</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Warrants that may be issued by CEL-SCI provide the holders the right to purchase a specific number of CEL-SCI&#8217;s shares at a fixed price at a future date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Rights Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">In October 2020, we declared a dividend of one Series A Right and one Series B Right, or collectively the Rights, for each share of our common stock which was outstanding on October 30, 2020. When the Rights become exercisable, each Series A Right will entitle the registered holder, subject to the terms of a Rights Agreement, to purchase from us one share of our common stock at a price equal to 20% of the market price of our common stock on the exercise date, although the price may be adjusted pursuant to the terms of the Rights Agreement. If after a person or group of affiliated persons has acquired 15% or more of our common stock or following the commencement of a tender offer for 15% or more of our outstanding common stock (i) we are acquired in a merger or other business combination and we are not the surviving corporation, (ii) any person consolidates or merges with us and all or part of our common shares are converted or exchanged for securities, cash or property of any other person, or (iii) 50% or more of our consolidated assets or earning power are sold, proper provision will be made so that each holder of a Series B Right will thereafter have the right to receive, upon payment of the exercise price of $100 (subject to adjustment), that number of shares of common stock of the acquiring company which at the time of such transaction has a market value that is twice the exercise price of the Series B Right.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The description and terms of the Rights are set forth in a Rights Agreement between the Company and Computershare Trust Company, N.A., as Rights Agent.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Distribution of Rights</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Initially, stockholders will not receive separate certificates for the Rights as the Rights will be represented by outstanding common stock certificates. Until the exercise date, the Rights cannot be bought, sold or otherwise traded separately from the common stock. Certificates for common stock carry a notation that indicates that Rights are attached to the common stock and incorporate the terms of the Rights Agreement.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Separate certificates representing the Rights will be distributed as soon as practicable after the earliest to occur of:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15 business days following a public announcement that a person or group of affiliated or associated persons has acquired beneficial ownership of 15% or more of our outstanding common stock, or</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15 business days (or such later date as may be determined by action of our board of directors prior to such time as any person or group of affiliated persons has acquired 15% or more of our common stock) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of our outstanding common stock.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The earlier of such dates described above is called the &#8220;distribution date.&#8221;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Until the distribution date (or earlier redemption or expiration of the Rights), the surrender for transfer of any certificates for common stock outstanding as of the record date, even without such notation, will also constitute the transfer of the Rights associated with the common stock represented by such certificate. As soon as practicable following the distribution date, separate certificates evidencing the Rights will be mailed to holders of record of the common stock as of the close of business on the distribution date and such separate right certificates alone will evidence the Rights.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Exercise and Expiration</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The holders of the Rights are not required to take any action until the Rights become exercisable. The Rights are not exercisable until the distribution date. Holders of the Rights will be notified by us that the Rights have become exercisable. The Rights will expire on October 30, 2025, unless the expiration date is extended or unless the Rights are earlier redeemed by us as described below.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Redemption</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">At any time prior to the distribution date, our board of directors may redeem the Rights in whole, but not in part, at a price of $0.0001 per Right. Subject to the foregoing, the redemption of the Rights may be made effective at such time, on such basis and with such conditions as our board of directors in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only entitlement of the holders of Rights will be to receive the redemption price.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Exchange Option</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">At any time after a person or group of affiliated persons has acquired 15% or more of our common stock or following the commencement of a tender offer for 15% or more of our outstanding common stock, and prior to the acquisition by such person of 50% or more of the outstanding common stock, our board of directors may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Other Provisions</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The terms of the Rights may be amended by our board of directors without the consent of the holders of the Rights, except that from and after such time a person or group of affiliated persons has acquired 15% or more of our common stock no such amendment may adversely affect the interests of the holders of the Rights.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Until a Right is exercised, the holder of the Right, as such, will not have any rights as a stockholder, including, without limitation, the right to vote or to receive dividends.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The Rights may have certain anti-takeover effects. The Rights will cause substantial dilution to a person or group that attempts to acquire us on terms not approved by our board of directors. However, the Rights should not interfere with any merger or other business combination approved by a majority of our board of directors because the Rights may be redeemed by us at any time prior to the distribution date. Thus, the Rights are intended to encourage persons who may seek to acquire control of us to initiate such an acquisition through negotiations with our board of directors. However, the effect of the Rights may be to discourage a third party from making a partial tender offer or otherwise attempting to obtain a substantial position in the equity securities of, or seeking to obtain control of, us. To the extent any potential acquisition is deterred by the Rights, the Rights may have the effect of preserving incumbent management in office.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:left;"><strong><em>Attorneys&#8217; Fees in Stockholder Actions</em></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Our bylaws include a fee-shifting provision in Article X for stockholder claims. Article X provides that in the event that any stockholder initiates or asserts a claim against us, or any of our officers or directors, including any derivative claim or claim purportedly filed on our behalf, and the stockholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then the stockholder will be obligated to reimburse us and any of our officers or directors named in the action, for all fees, costs and expenses of every kind and description, including but not limited to all reasonable attorneys&#8217; fees and other litigation expenses, that we or our officers or directors who were named in the action may incur in connection with such claim.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Our fee-shifting provision is not limited to specific types of actions, but is rather potentially applicable to the fullest extent permitted by law. There are several types of remedies that a stockholder may seek in connection with an action or proceeding against us, including declaratory or injunctive relief, or monetary damages. If a stockholder is not successful in obtaining a judgment that substantially achieves in substance, such as in the case of a claim for declaratory or injunctive relief, or amount, such as in the case of a claim for monetary damages, our and our officers&#8217; and directors&#8217; litigation expenses may be shifted to the stockholder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Fee-shifting provisions are relatively new and untested. The case law and potential legislative action on fee shifting bylaws are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such bylaws. For example, it is unclear whether our ability to invoke our fee-shifting bylaw in connection with claims under the federal securities laws, including claims related to this offering, would be pre-empted by federal law. Similarly, it is unclear how courts might apply the standard that a stockholder must obtain a judgment that substantially achieves, in substance and amount, the full remedy sought. The application of our fee shifting bylaw in connection with such claims, if any, will depend in part on future developments of the law. We cannot assure you that we will or will not invoke our fee-shifting bylaw in any particular dispute, including any claims related to this offering.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">If a stockholder that brings any such claim is unable to obtain the required judgment, the attorneys&#8217; fees and other litigation expenses that might be shifted to such a stockholder are potentially significant. This fee-shifting bylaw, therefore, may dissuade or discourage stockholders (and their attorneys) from initiating lawsuits or claims against us or our directors and officers. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs&#8217; attorneys to represent our stockholders or otherwise discourage plaintiffs&#8217; attorneys from representing our stockholders at all. As a result, this bylaw may limit the ability of stockholders to affect the management and direction of our company, particularly through litigation or the threat of litigation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Transfer Agent</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Computershare, Inc., of Denver, Colorado, is the transfer agent for CEL-SCI's common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="legal">LEGAL MATTERS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The validity of the securities being offered by this prospectus will be passed upon for us by Hart &amp; Hart, Denver, Colorado.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="export">EXPERTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The financial statements as of September 30, 2023 and 2022 and for the years then ended incorporated by reference in this Prospectus and in the Registration Statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting.&nbsp;The report on the Financial Statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="INDEMNIFICATION">INDEMNIFICATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI's bylaws authorize indemnification of a director, officer, employee or agent of CEL-SCI against expenses incurred by such person in connection with any action, suit, or proceeding to which such person is named a party by reason of such person having acted or served in such capacity, except for liabilities arising from such person's own misconduct or negligence in performance of such person's duty.&nbsp;&nbsp;In addition, even a director, officer, employee, or agent of CEL-SCI who was found liable for misconduct or negligence in the performance of his duty may obtain such indemnification if, in view of all the circumstances in the case, a court of competent jurisdiction determines such person is fairly and reasonably entitled to indemnification.&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers, or persons controlling CEL-SCI pursuant to the foregoing provisions, CEL-SCI has been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is therefore unenforceable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="ADDITIONALINFORMATION">ADDITIONAL INFORMATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI is subject to the requirements of the Securities Exchange Act of l934 and is required to file 10-K, 10-Q, 8-K reports, proxy statements and other information with the Securities and Exchange Commission.&nbsp;&nbsp;The Commission maintains an Internet site that contains reports, proxy and information statements, and other information regarding CEL-SCI.&nbsp;&nbsp;The address of that site is http://www.sec.gov.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI has filed with the Securities and Exchange Commission a Registration Statement under the Securities Act of l933, as amended, with respect to the securities offered by this prospectus.&nbsp;&nbsp;This prospectus does not contain all of the information set forth in the Registration Statement.&nbsp;&nbsp;For further information with respect to CEL-SCI and such securities, reference is made to the Registration Statement and to the exhibits filed with the Registration Statement.&nbsp;&nbsp;Statements contained in this prospectus as to the contents of any contract or other documents are summaries which are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each such statement being qualified in all respects by such reference.&nbsp;&nbsp;The Registration Statement and related exhibits may also be examined at the Commission&#8217;s internet site. &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI will provide, without charge, to each person to whom a copy of this prospectus is delivered, including any beneficial owner, upon the written or oral request of such person, a copy of any or all of the documents incorporated by reference below (other than exhibits to these documents, unless the exhibits are specifically incorporated by reference into this prospectus). Requests should be directed to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8229 Boone Blvd., #802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Vienna, Virginia&nbsp;&nbsp;22182</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(703) 506-9460</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">INCORPORATION OF DOCUMENTS BY REFERENCE &#8211; We incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by this Registration Statement, and any future filings we will make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Annual Report on Form 10-K for the fiscal year ended September 30, 2023;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Quarterly Reports on Form 10-Q for the periods ended December 31, 2023, March 31, 2024 and June 30, 2024;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Current Reports on Form 8-K filed with the SEC on October 24, 2023, October 30, 2023, November 20, 2023, February 13, 2024, April 19, 2024, April 23, 2024, June 20, 2024, July 26, 2024, July 29, 2024 and September 17, 2024;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Proxy Statement relating to our April 19, 2024 Annual Meeting of Shareholders; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 2, 1996 and all amendments and reports updating that description</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">All documents filed with the Commission by CEL-SCI pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this prospectus and prior to the termination of this offering shall be deemed to be incorporated by reference into this prospectus and to be a part of this prospectus from the date of the filing of such documents.&nbsp;&nbsp;Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained in this prospectus or in any subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement.&nbsp;&nbsp;Such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The documents incorporated by reference may be accessed at the website of the Securities and Exchange Commission: <u>www.sec.gov</u> and at CEL-SCI's website:&nbsp;<u>www.cel-sci.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Investors are entitled to rely upon information in this prospectus or incorporated by reference at the time it is used by CEL-SCI to offer and sell securities, even though that information may be superseded or modified by information subsequently incorporated by reference into this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="TOC">TABLE OF CONTENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:1%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:6%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#prospe">Prospectus Summary</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#forward">Forward Looking Statements</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#business">Business Overview</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#risk">Risk Factors</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">15</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#uesof">Use of Proceeds</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">15</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#dilutio">Dilution</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">15</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#plan">Plan of Distribution</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">15</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#descript">Description of Securities</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">17</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#legal">Legal Matters</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#export">Experts</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">21</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#INDEMNIFICATION">Indemnification</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">21</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="#ADDITIONALINFORMATION">Additional Information</a></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">21</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PROSPECTUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;_________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">No dealer salesman or other person has been authorized to give any information or to make any representations, other than those contained in this prospectus. Any information or representation not contained in this prospectus must not be relied upon as having been authorized by CEL-SCI. This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, the securities offered hereby in any state or other jurisdiction to any person to whom it is unlawful to make such offer or solicitation. Neither the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create an implication that there has been no change in the affairs of CEL-SCI since the date of this prospectus.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART II</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Information Not Required in Prospectus</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 14. <u>Other Expenses of Issuance and Distribution</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">SEC Filing Fee</p></td> <td style="width:1%;white-space: nowrap;"></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,905</td> <td style="width:1%;white-space: nowrap;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Legal Fees and Expenses</p></td> <td style="width:1%;white-space: nowrap;"></td> <td style="width:1%;white-space: nowrap;"></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500</td> <td style="width:1%;white-space: nowrap;"></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Accounting Fees and Expenses</p></td> <td style="width:1%;white-space: nowrap;"></td> <td style="width:1%;white-space: nowrap;"></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;white-space: nowrap;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Miscellaneous Expenses</p></td> <td style="width:1%;white-space: nowrap;"></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">500</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">TOTAL</p></td> <td style="width:1%;white-space: nowrap;"></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">31,905</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">All expenses other than the SEC filing fees are estimated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 15.&nbsp;&nbsp;<u>Indemnification of Officers and Directors</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Section 7-109-102 of the Colorado Revised Statutes and CEL-SCI's Bylaws<strong>,</strong>&nbsp;CEL-SCI may indemnify any and all of its officers, directors, employees or agents or former officers, directors, employees or agents, against expenses actually and necessarily incurred by them, in connection with the defense of any legal proceeding or threatened legal proceeding, except as to matters in which such persons shall be determined to not have acted in good faith and in the best interest of CEL-SCI.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 16.&nbsp;&nbsp;<u>Exhibits </u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="2"> <tr style="height:15px;background-color:#cceeff"> <td style="padding:2px;width:8%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3(a)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;width:30%;vertical-align:top;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Articles of Incorporation</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3(b)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Amended Articles</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3(c)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Amended Articles (Name change only)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 3(c) of CEL-SCI's Registration Statement on Form S-1 Registration Statement (No. 33-34878).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(d)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bylaws (as amended)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">4</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">Shareholders Rights Agreement, as Amended</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 filed with CEL-SCI&#8217;s 8-K report dated October 30, 2020.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">4(b)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">Incentive Stock Option Plan</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on October 7, 2016 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-214031).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495424011346/cvm_ex4b.htm">4(c)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495424011346/cvm_ex4b.htm">Non-Qualified Stock Option Plan</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on August 30, 2024 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-281884).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015936/cvm_ex4c.htm">4(d)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015936/cvm_ex4c.htm">Stock Bonus Plan</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (d) filed on December 22, 2023 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-276238).</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">4(e)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">Stock Compensation Plan</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (e) filed on January 24, 2020 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-236063.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4(f)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2014 Incentive Stock Bonus Plan</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed with Amendment No. 2 to CEL-SCI&#8217;s annual report on Form 10-K for the year ended September 30, 2014.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex5.htm">5</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex5.htm">Legal Opinion </a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;___________________</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="2"> <tr style="height:15px;background-color:#cceeff"> <td style="padding:2px;width:8%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">10(l)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;width:30%;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">First Amendment to Development Supply&nbsp;</a><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">and Distribution Agreement with Orient&nbsp;Europharma.</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(m)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2010.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">10(m)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">Exclusive License and Distribution&nbsp;Agreement </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">with Teva&nbsp;Pharmaceutical Industries&nbsp;Ltd.</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(n)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2010.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">10(n)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">Lease Agreement</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(o)&nbsp;filed with CEL-SCI&#8217;s 10-K report for the&nbsp;year ended September 30, 2010.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10(p)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Licensing Agreement with Byron&nbsp;Biopharma</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(i) of&nbsp;CEL-SCI&#8217;s report on Form 8-K dated March&nbsp;27, 2009</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10(z)</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Development, Supply and Distribution&nbsp;Agreement with Orient Europharma</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit&nbsp;10(z)&nbsp;filed with CEL-SCI&#8217;s report on Form&nbsp;10-K for the year ended September 30, 2003.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">10 (rr)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">Assignment and Assumption Agreement with </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">Teva Pharmaceutical Industries, Ltd. and </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">GCP Clinical Studies, Ltd.</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(rr) of CEL-SCI&#8217;s report on Form 10-K/A report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">10 (ss)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">Service Agreement with GCP Clinical Studies,</a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">&nbsp;Ltd., together with Amendment 1 thereto*</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ss) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">10 (tt)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">Joinder Agreement with PLIVA Hrvatska d.o.o.</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(tt) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">10 (uu)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">Master Service Agreement with Ergomed </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">Clinical Research, Ltd.,&nbsp;and Clinical Trial </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">Orders thereunder</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(uu) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">10 (vv)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">Co-Development and Revenue Sharing </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">Agreement with Ergomed Clinical Research </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">Ltd., dated April 19, 2013, as amended</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 10(vv) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">10 (ww)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Co-Development and Revenue Sharing </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Agreement II:&nbsp;&nbsp;Cervical ntraepithelial Neoplasia </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">in HIV/HPV co-infected women, with </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Ergomed Clinical Research Ltd., dated </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">October 10, 2013, as amended</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 10(ww) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">10(xx)</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">Co-Development and Revenue Sharing </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">Agreement III: Anal warts and anal </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">intraepithelial neoplasia in HIV/HPV</a>&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">co-infected patients, with Ergomed </a><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10xx.htm">linical Research Ltd., dated October 24, 2013</a></p></td> <td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 10(xx) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&nbsp;year ended September 30, 2014 dated April 17, 2015.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:8%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">10 (yy)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;width:30%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">Master Services Agreement with Aptiv Solutions, Inc.</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(yy) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">10 (zz)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">Project Agreement Number 1 with Aptiv</a>&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">Solutions, Inc. together with Amendments 1</a>&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">and 2 thereto*</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(zz) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">10 (aaa)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">Second Amendment to Development Supply</a>&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">and Distribution Agreement with</a>&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">Orient Europharma</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(aaa) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the year ended September 30, 2014 dated April 17, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10 (iii)</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Amendment to Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research, Ltd., dated September 15, 2015</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10 (iii) filed with CEL-SCI&#8217;s 10-K report for the year ended September 30, 2015.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">10 (mmm)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">Employment Agreement with Geert Kersten (2019-2023)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.7) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">10 (nnn)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">Employment Agreement with Patricia Prichep (2019-2022)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.8) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">10 (ooo)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">Employment Agreement with Eyal Taylor (2019-2022)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.9) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">10 (ppp)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">Extension of Employment Agreement with Patricia Prichep (2023-2027)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.10) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">10 (qqq)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">Extension of Employment Agreement with Eyal Taylor (2023-2027)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.11) of CEL-SCI&#8217;s report on Form 8-K dated August 21, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_ex1010.htm">10 (rrr)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_ex1010.htm">Extension of Employment Agreement with Geert Kersten (2019-2023)</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10.10 of CEL-SCI&#8217;s report on Form 8-K dated October 26, 2023.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex231.htm">23.1</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex231.htm">Consent of Hart &amp; Hart, LLC</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">____________________</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex232.htm">23.2</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex232.htm">Consent of BDO USA, P.C.</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">____________________</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015877/cvm_ex97.htm">97</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015877/cvm_ex97.htm">Policy relating to Recovery of Erroneously Awarded Compensation</a></p></td> <td style="PADDING-BOTTOM: 2px; PADDING-TOP: 2px; PADDING-LEFT: 2px; PADDING-RIGHT: 2px;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incorporated by reference to Exhibit 97 of CEL-SCI&#8217;s 10-K report for the year ended September 30, 2023.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 of the Securities Exchange Act of 1934. The omitted confidential material has been filed separately with the Commission. The location of the omitted confidential information is indicated in the exhibit with asterisks (*)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Item 17. <u>Undertakings</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The undersigned registrant hereby undertakes:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To include any prospectus required by Section l0(a)(3) of the Securities Act;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(ii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(iii)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement, including (but not limited to) any addition or deletion of a managing underwriter.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">That, for the purpose of determining any liability under the Securities Act of l933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Insofar as indemnification for liabilities arising under the Securities Act of l933 (the &#8220;Act&#8221;) may be permitted to directors, officers and controlling persons of the Registrant, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>POWER OF ATTORNEY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The registrant and each person whose signature appears below hereby authorizes the agent for service named in this registration statement, with full power to act alone, to file one or more amendments (including post-effective amendments) to this registration statement, which amendments may make such changes in this registration statement as such agent for service deems appropriate, and the Registrant and each such person hereby appoints such agent for service as attorney-in-fact, with full power to act alone, to execute in the name and in behalf of the Registrant and any such person, individually and in each capacity stated below, any such amendments to this registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Act of l933, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vienna, State of Virginia, on the 8 <sup style="vertical-align:super">th </sup>day of October 2024.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CEL-SCI CORPORATION</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;">/s/ Geert Kersten</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Geert Kersten, Chief Executive, Financial and</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Accounting Officer</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Pursuant to the requirements of the Securities Act of l933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Signature</strong></p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Title</strong></p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Date</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive, Financial and</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Accounting Officer and a Director</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 8, 2024</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Robert Watson</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Director, Chairman of the Board</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 8, 2024</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&nbsp;Bruno Baillavoine</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 8, 2024</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Mario Gobbo</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">October 8, 2024</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBITS</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>REGISTRATION STATEMENT ON FORM S-</strong><strong>3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5
<SEQUENCE>2
<FILENAME>cvm_ex5.htm
<DESCRIPTION>LEGAL OPINION
<TEXT>
<html><head><title>cvm_ex5.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 5</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><em><font style="font-size:14pt">HART &amp; HART, LLC</font></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ATTORNEYS AT LAW</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1624 Washington Street</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Denver, CO&nbsp; 80203</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:25%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">William T. Hart, P.C.</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">____________</p></td> <td style="width:25%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">harttrinen@aol.com</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Will Hart</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(303) 839-0061</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;Fax: (303) 839-5414</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">October 8, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">8229 Boone Blvd. #802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Vienna, VA 22182</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">This letter will constitute an opinion upon the legality of the sale by CEL-SCI Corporation, a Colorado corporation (&#8220;CEL-SCI&#8221;), or certain selling shareholders of CEL-SCI, of shares of its common stock, preferred stock, convertible preferred stock, rights, units, and<strong> </strong>warrants, as well as any securities issuable upon the conversion of preferred stock or upon exercise of warrants, having a maximum value of $150,000,000 all as referred to in the Registration Statement on Form S-3 filed by CEL-SCI with the Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We have examined the Articles of Incorporation, the Bylaws and the minutes of the Board of Directors of CEL-SCI and the applicable laws of the State of Colorado, and a copy of the Registration Statement, and such other documents as we considered necessary for purposes of this opinion. In our opinion:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">CEL-SCI is authorized to issue the securities which are the subject of the Registration Statement;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">such securities, when sold, will be legally issued, fully paid and non-assessable; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the warrants and rights will be, when issued, binding obligations of CEL-SCI under the laws of Colorado; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">any shares to be sold by the selling shareholders of CEL-SCI have been legally issued and represent fully paid and non-assessable shares of CEL-SCI&#8217;s common stock.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:53%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;vertical-align:top;">Very truly yours,</td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">HART &amp; HART, LLC</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ William T. Hart</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">William T. Hart</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSENT OF ATTORNEYS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Reference is made to the Registration Statement of CEL-SCI Corporation, whereby the Company, or certain selling shareholders, propose to sell securities having a maximum value of $150,000,000. Reference is also made to Exhibit 5 included in the Registration Statement relating to the validity of the securities proposed to be sold.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We hereby consent to the use of our opinion concerning the validity of the securities proposed to be issued and sold.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;vertical-align:top;">Very truly yours,</td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;">HART &amp; HART, LLC</td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ William T. Hart</td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;">Denver, Colorado</td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;">October 8, 2024</td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>cvm_ex232.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex232.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><u>Consent of Independent Registered Public Accounting Firm</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, Virginia</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We hereby consent to the incorporation by reference in the&nbsp;Form S-3 Post-Effective Amendment No. 1 to the Prospectus&nbsp;constituting a part of this Registration Statement of our report dated December 21, 2023, relating to the financial statements of CEL-SCI Corporation (the Company) appearing in the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023. Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We also consent to the reference to us under the caption &#8220;Experts&#8221; in the Prospectus.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:53%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;vertical-align:top;"><em>/s/ BDO USA, P.C.</em></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Potomac, Maryland</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">October 8, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>cvm_ex107.htm
<DESCRIPTION>FILING FEE TABLES
<TEXT>
<html><head><title>cvm_ex107.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 107</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Calculation of Filing Fee Tables</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>S-3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Post-Effective Amendment No. 1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Form Type)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cel-Sci Corporation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Table 1: Newly Registered and Carry Forward Securities</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:15%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Security</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Type</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Security Class</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Title</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fee</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Calculation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>or Carry</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Forward</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Rule</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Registered</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:5%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proposed</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Maximum</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Offering</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Price Per</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Unit</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Maximum</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Offering</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Price </strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fee Rate</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount of</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Registration</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fee</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Forward</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Form Type</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward File Number</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward Initial effective date</strong></p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:3%;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</strong></p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Fees to be Paid</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Equity</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Common Stock, Preferred Stock, Rights and Warrants</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Rule 457(o)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$150,000,000 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$92.70 per 1,000,000</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$13,905 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Fees Previously Paid</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Carry Forward Securities</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Offering Amounts</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$150,000,000 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$13,905 </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Fees Previously Paid</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">($13,905)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Fee Offsets</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">--</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Net Fee Due</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">--</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Table 2 &#8211; Fee offset claims and sources</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Table 3 &#8211; Combined prospectuses</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>cvm_s3aimg9.jpg
<TEXT>
begin 644 cvm_s3aimg9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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M@:UCNV3,B1,<L@/H3VKG)?A3\-9["VT^;P3I#6MM))-!"ULI6)GQOVCL#@9
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M]]BC[5;_ //Q'_WV* )J*A^U6_\ S\1_]]BC[5;_ //Q'_WV* )J*A^U6_\
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M5%;_ /'K#_N#^52TB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **JM-EBL,9D(ZD' 'MFG^;<?\^I_[[% $]%0>;<?\^I_[[%'F
MW'_/J?\ OL4 3T5!YMQ_SZG_ +[%'FW'_/J?^^Q0!/14'FW'_/J?^^Q1YMQ_
MSZG_ +[% $]%0>;<?\^I_P"^Q1YMQ_SZG_OL4 3T5!YMQ_SZG_OL4>;<?\^I
M_P"^Q0!/14'FW'_/J?\ OL4>;<?\^I_[[% $]%0>;<?\^I_[[%'FW'_/J?\
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MC_GU/_?8H GHJ#S;C_GU/_?8H\VX_P"?4_\ ?8H GHH'3THH **** "BBB@
MHHHH **** "BBH9)ECP,%G/W4'4T 2,RHI9F 4=2:J_OK@]TA_)G_P !^M$<
M+.XDGY8<J@^ZO^)]ZN4 -5510JJ%4= *=110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !0>E%!Z4 ?%7CK_DH.O\ _7_/_P"C&K,L='U;5HY)
M-+TV[ODBX=H(6<+]2!6GXY_Y*#K_ /U_S_\ HQJM_#W3UDUD:M>>)(K6QTV<
M7$>FM?I!)>7  V@!V "],L>W [U]S]8E0PL)1[(^-=-5*SB^[,.QT'7-4CFD
MTW1[V\6 [9##"SB,^AP.#[5'!H^K75E<7UKI=U-:VO\ KI8X69(_7<<<5VWA
M6WN+CQQJ?B;6O$5E;"ROI+Q-)@U2-!=W+8("DL%\L9 +\YQCUJEH?C*\AU^?
M0]4L[2.\GU"[D6_CO@EK;_:%Q,S@96557)7!'.!67]J5[M0BG:W_  ?4W6&A
M9<SM<XZ6UNH(+>XGMY(HKE2\+LN!*H."5]1D$9KFO$/^LMOHW]*]GN+KP/XB
M\,7&IK]EA\BUN;:W$MT4N;00E5LXXX<_,'&68X/+'D5XQXA^_;?[K?TKKHXO
MZQ3ES)IK_,P]E[*HM;W,.OM7]G7_ )(U9_\ 7U/_ .A5\55]J_LZ_P#)&K/_
M *^I_P#T*O(S7^#\U^I[&"_B?(]>JIJ7_(+N_P#KB_\ Z":MU4U+_D%W?_7%
M_P#T$U\NCV62V_\ QZQ?[H_E4U0V_P#Q[1?[H_E4U#W!!1110,**** "BBB@
M HHHH **** "J5U-);VTD\=O)=.BY6*+&YSZ#) _,U=K.U1M2&E7/]C^1]OV
M'R?M.1&&]6QSB@#"_P"$NA6.X2XTVZBU&&YCM/L6Y&=Y)%#)M8-MP5.2<\8/
MI4$WC:TM[(3?V==/<1M.+FV&S=;B  RDDM@X#*1@G(88JK;^'=87286^SVJ:
ME;7Z:BTLETTIO9,%7WMY:[,J<# (7 &,"KL/A7SM+OFU:SM+O4KFZEO4C8L8
MHG90JINP"R[54-QSSQ0!N6>HKJ%Y=);JQCMG6,R'&UV*AB!WX!&??CL:UJX"
MW\(:A:^)+&\ANHS% 8W>X9F$V0K^:@7&TB1WWDYZYX.!COZ *DDS,YBA 9A]
MYC]U?\3[5+%"L8+<L[?>8]34BJJ*%50H'84Z@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *#THH[4 ?'GB/0=5USQQXNN-,MOM*
MZ=>2RSJK?.%:5@-J]6Z=JYS5O!>K:3JDUG?:1))<PG#F >:N?+\P@,."0GS'
MT%;?B;7-<T+QUXQCT2]-F][?MNGCXEC,<K$;#VZD'@\54_X3[Q0PG62"PE,J
M\,\;9C/V?[.67YNICZYSSS7V-+ZTZ4>6*<;*W?9'RLXT>9W;3O\ J)-\-]:@
MFCD:SBDA:=+;SXMTBAVC60<*I;&' R!UXJ*;P?JBRVJR6X:&>V6Z2=$=XP#&
M9 I(4_-M!)&.._'-2Q^.O$B7<5TUMI\DL%U%>0LT3?NI$A6'(PPR"B@$'/.2
M,4S_ (3CQ,UCI]G-#8R)IT#6UJQA.Z)'A,+@'=SN4Y.>X!]JN-/%K[*):HOJ
MRC_PB^M0S6^=!ODDNL^2#;MF3Y=QQQSP<_3FN5\4V\]K>16UU"\$\6Y7CD4J
MRGC@@]*[Z'XA>+(;GSH39C=)YCKY;88?9U@*_>R!L4'@@YYSVKB/&FI76KZN
M-2O,?:+C+/@L1P .K$D\#N378O;.+52*2\N]S-1IJ2<7<Y>OM;]G;_DC-E_U
M\S_^A5\4U]K?L[?\D:LO^OF?_P!"KQ\U_@_-?J>O@OXGR/7:J:E_R"[O_KB_
M_H)JW534O^07=_\ 7%__ $$U\NCV&2V__'K%_NC^535#;_\ 'M%_NC^534/<
M$%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBF22)&FZ1
ML"@!]%4AYTWS;FA3LHQN/UST^E3>1)_S]2_DO^% $]%0>1)_S]2_DO\ A1Y$
MG_/U+^2_X4 3T5!Y$G_/U+^2_P"%'D2?\_4OY+_A0!/14'D2?\_4OY+_ (4>
M1)_S]2_DO^% $]%0>1)_S]2_DO\ A1Y$G_/U+^2_X4 3T5!Y$G_/U+^2_P"%
M'D2?\_4OY+_A0!/14'D2?\_4OY+_ (4>1)_S]2_DO^% $]%0>1)_S]2_DO\
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MI*ZQ;:C'')']GV;8$D(B+(I1&*^JJQ _#T%=)0!4,<EP?WF4B_N=V^OM[59
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M!=H (&.&//S"N]KYB^ O_)1I_P#KPD_]#2OIV@ HHHH **** "BBB@ HHHH
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MY4?_ #S7\JS[J./^V-/_ ':])>WL*I;DRV%^R:?_ ,_DW_@8_P#\51]DT_\
MY_)O_ Q__BJO^5'_ '%_*CRH_P#GFOY4KON.R[%#[)I__/Y-_P"!C_\ Q5'V
M33_^?R;_ ,#'_P#BJO\ E1_\\U_*CRH_^>:_E1=]PLNQF:?+'%->0_:MZ),
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M]@DY)Q_&E?3/VBW_ .>\?_?0KYG^ ZJWQ$G#*"/L$G7_ 'TKZ:\J/_GFOY4
M-^T6_P#SWC_[Z%'VBW_Y[Q_]]"G>5'_SS7\J/*C_ .>:_E0 W[1;_P#/>/\
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M?:XWM6$@#/&&E59#EU#]0&/)%=+%:Z!-;6$+0HR1O?1SW4=RJL6B+>6&'^T
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MUSX G_BY,_\ V#Y/_0TKZCKY:_9__P"2DS_]@^7_ -#CKZEH **** "BBB@
MHHHH *J7<,D]E/!%)Y;R1LBO_=)& :MT4 >7:?X,\0:?JEC>QV7AS?96R0(H
M65067_EKC&-^"1GJ,GGFO4:** "BBB@ HHHH **** "BF,RHI9F"J.I/:JW[
MZXZ92'UZ,_\ @/UH :TWSE(4,A7[V" !^/K7@/[03.VL:)OC*?N).I!_B%?0
MNQ4PJJ !T KY_P#CU:W%]XF\.V-G'YMS<(T<48P"[%P !FO1RYJ->+?9_D<&
M/5Z+7I^9P'PYU"&W;Q7;R36\\UQ8I%#I<UV+(WGS_-MN"1Y94?GD>E3_ !,M
MH_$&O:MJ6EZM9,EAI]N9HGN59HS@@PHPSYS+C).>_6N1O_"NJ6]LUY?:3,D*
MW#VC,RY_>IRZX'/&#D]..M/L_"NL:A8K=V>DR3QEY(PJ@;P4C$C?*><;2#GO
MGC->I*$?:2J*:UT_(\;F;@J;CL=WXJN8]4\)ZKJ6O+9V&IVT<$6FMI^M?:TU
M#;@8:$' &!DG:I_*EC^(6GZI93Z]>VKV#0:@LD?VB[$[+=3(L1>)< I%%&'D
MYS\Q6N 7PS?6NGOJ$-FK0!HT8Q$,X9U9E4J.<X1B>.,<U!=:/<0O()+4R!%#
M/+$I=%! ;EAP.",^E:1PU.45'GNU^"TNMQ.4D[\O]=SH_B=I/A_3=,5M'\F.
M622=62"_^UB:!67RIV.3M9\DE<_A7CM=9J=LUKHTH-N\*R)N4LA4.,CD9ZCW
MKD2:]+V;I1C%RYG;?YBA)2O)*Q[G^S*SK\1M5VQES_9C\!@/^6L?K7UOYMQ_
MSZM_WVM?)7[+_P#R4G5/^P6__HV.OK_O7RF8?QWZ(]_"?PS+M)9_MFH?Z*W^
MN7^-?^>:5<\VX_Y]6_[[6HK/_C]U'_KLO_HM*O5P,ZD5O-N/^?5O^^UH\VX_
MY]6_[[6K-%(96\VX_P"?5O\ OM:/-N/^?5O^^UJS10!6\VX_Y]6_[[6CS;C_
M )]6_P"^UJS10!6\VX_Y]6_[[6E\Z;'_ !ZM_P!]+_C5B@]* /A7QXQ/Q'\2
M%EVG^TKCCK_RT:N:S71_$ _\7)\2_P#82N/_ $8U<SFOTK!?P(^B_(^0J_&_
M4?FC-,S1FNLQ'YKM? S?N;__ 'D_D:X?-=IX'/[F_P#]Y/Y&O)S7_=Y?+]#N
MP/\ 'C\_R.TW4;JBW4;J^ /IR7=1NJ+=1NH J:VW_$@O?^N1KS<FO1-:;_B0
MWO\ US-><$T >M_ %V7XD7!6,N?[/EX! _C2OJ'S;C_GU;_OM:^7OV>S_P 7
M,N/^P?+_ .AQU]54 5O-N/\ GU;_ +[6CS;C_GU;_OM:LT4 5O-N/^?5O^^U
MH\VX_P"?5O\ OM:LT4 ';THHHH **** "BBB@ HK#\0ZY_8%C!<&W^T//<);
MHGFK&-S9Y+-P!Q69>>+7TV&VDO-*F$CPO=3)%,CB&!652^<X;[ZG YZT =?1
M69I^HQZ@]WY,;"*"9H!(>DI7ABOL&ROU4UIT %123+&!G+,?NJ.IJ%YF9C%"
M SCJQ^ZOU]_:I8X5CRV=SG[SGJ: (5A:1Q)<8)'*H/NK_B:N444 1GJ:^>/C
MUJ$VD^-?"6L6\*S261-PL;DA7*N#@D=C7T+U85\Z_M&'&MZ#_P!>\G_H0KT<
MNBIXB,7LT_R.''-JBVO(\[_X6=XFF@CAU2V@U-4EE.9',9,4D#0F/*^@8G=U
M)ZYIO_"R-8^V+,NCP1Q[GW1I<R*2C6BVVW=U&%0,#UW5R&ZC=7U_]GT/Y3YW
MZS4[G80?$C6(-/N--&CV[VL]G%8R%IW\SRXXGC!#]0Q$F21Z8Z$T2?$K7FC>
M-=-A1)-ZN@F?:X:T6VY'0X"AQGO7'[J-U:_V=A][!]9J=S?\<>.-4\7:!%'J
M5K';FU!8")R4R0JG:N/E'R@XR:\L)KJ=3;_B5W'^[_45R9-*O3C2Y805DE^I
MO2E*=Y2W/>?V7?\ DI6J?]@M_P#T;'7V$/O&OCS]ET_\7+U7_L%O_P"C8Z^P
MQ]XU\9F'\=^B/>PG\,I6?_'[J/\ UV7_ -%I5ZJ-G_Q^ZC_UV7_T6E7J\]G4
M@HHHI#"BBB@ HHHH *#THH/2@#X0\??\E)\2?]A*X_\ 1C5S==)\0#_Q<KQ+
M_P!A*X_]&-7,YK]'P;_<Q]%^1\A5^-^HZBFYHS79<R'5V7@DXBOO]Y/Y&N+S
M78>"S^ZOO]Y/Y&O)S;_=Y?+\T=V!_C1^?Y'8[J-U1;J-U?!'TQ+NHW5%NHW4
M 5=:;_B17O\ US-><DUZ#K+?\2.\_P"N9KSLF@#V#]GD_P#%S;C_ +!\O_H<
M=?5E?*/[/!_XN=<?]@Z7_P!#CKZNH **** "BBB@ HHHH **** "BBB@#%UB
MWN[JS6*UL[&].\%X;[(1EP>A"M@YQV/>L"W\(K'X9BLIH;&?489)I[9F0^3:
MO(Y<*@Z[%R, ]=HX';N:* .%L_"%QI_BJVOK?R!:0$%92S&X9/(\LPGC&PO^
M\)S]X].]=U110 U55%"JH4>@IU%% !1110 ROF_]I XUO0O^O>3_ -"%?2%?
M-O[29QKF@_\ 7O)_Z$*]/*_]ZC\_R.#&_P %_(\+W4;JAW4;J_1+GS%B;=1N
MJ'=1NHN%B+4F_P")9/\ [O\ 6N4)KIM2;_B63_[O]:Y8FO,Q;]]>AV4/A/??
MV63_ ,7+U7_L%O\ ^C8Z^Q*^./V5S_Q<S5O^P6__ *-CK['KXC&_QF?08;^&
M4K/_ (_=1_Z[+_Z+2KU4;/\ X_=1_P"NR_\ HM*O5QLZ4%%%%(84444 %%%%
M !0>E%!Z4 ?!_P 03_Q<WQ+_ -A*X_\ 1C5S&:Z;XA?\E-\2_P#82N/_ $8U
M<O7Z-@_X,?1?D?(5?C?J.S1FFT5V$#LUUW@UOW5[_O)_(UQ]=;X/;$5[_O+_
M "->3FG^[S^7YH[<#_&C\_R.NW4;JAW4;J^#/I2;=1NJ'=1NH K:PW_$CO/^
MN9KSTFN]UAO^))>?]<S7GQ- 'L?[.Q_XN?<?]@Z7_P!#CKZPKY,_9U/_ !="
MX_[!TO\ Z''7UG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3
M))$C0O(VU1WJ*28(0BKOD/11_7T%(D98B29@[]L=%^G^- $ \Z4[PQA7L, L
M?KGI]*^<_P!I)677/#^Z1G_T>3J!_>'I7TS7S/\ M,-_Q/?#XS_R[R?^A"O4
MRK_>H_/\CAQG\%_(\&W4;JBW4;J^^N?-6)=U&ZHMU&ZBX6(M1;_B6S_[O]:Y
M<FNCU!O^)=/_ +O]:YEF '6O,Q;]Y>AV4%[I[Y^RVK'XF:MMD*?\2I^@'_/6
M/UK[&\F7_GZD_P"^5_PK\_/@W<^(O^$^GC\.:VFB!;"::^O6A\WRK:/#N0F1
MDY"X&:[?QE\5OB5X;T[P_KND^-3JNB>(+5KJSN)K(02KM;:Z.FY@"#CH37QF
M+G&=5N+N>_AXN,+,^Q8;-HY9YENI,S,&;(7@A0OI[58\F7_GZD_[Y7_"OERT
M\1?$^XT>RCD^( B\3ZAH;^(+73/[/S"]LO(0S;N)",D#;CWHDU[XO7'A33[[
M2O&KWFLW,>FS-9-I_EP;;TD1".;=\[+C+C P,GM7&=!]1^3+_P _4G_?*_X4
M>3+_ ,_4G_?*_P"%?%/BSXK?&#PW?RR1ZI>SZ(\S0V6JSZ>88KW;U>//!4D$
MCGD8--\/?%CXQ:[/'MUQD@8\$0C<_P!/\: /MCR9?^?J3_OE?\*/)E_Y^I/^
M^5_PKSCP)9^.KF%+SQ%K4S(W(C( KTM1M4 G/O0!'Y,O_/U)_P!\K_A1Y,O_
M #]2?]\K_A4U% $/DR_\_4G_ 'RO^%)Y,N/^/J3_ +Y7_"IZ#TH ^"?B!D?$
MKQ*"Q8_VE<<GO^\:N:KI?B"P/Q,\3$<C^TKC_P!&-7,9K]%PC_<Q]$?)5?C?
MJ.HIN:,UU7,QU=7X1.(KS_>7^1KDLUU/A)OW5Y_O+_6O*S7_ ':?R_-';@OX
ML?G^1U>ZC=46ZC=7PI](2[J-U1;J-U %;5V_XDMW_P!<S7 $UW>KM_Q);O\
MZYFN!Y8X')H ]A_9WW-\3KC:Y3_B72\C']^/UKZR\F7_ )^I/^^5_P *^*_A
MS8^*[?7Q=^&Y9+:ZD0PM(JYPI()S^0KZV\,:?KEK8(VMZI)=SD<Y[4 ;WDR_
M\_4G_?*_X4>3+_S]2?\ ?*_X5-10!#Y,O_/U)_WRO^%)Y4O_ #]/^2_X5/10
M #IZT444 %%%% !1110 45S'B&\ODN=)TVQN39RZC=&)K@(K-&BQO(=H;(R=
M@'(/4\5S<VO>*'LXA:R222VT]U;/-#:AUN9HIE1!)P1&K)N)88 (/(Q@@'I=
M%<9I/BB"_OY+>XDE#7$Q^R#R2(U39N5"^,;V0>;@] P]*[.@ JHTKR,4M^@X
M:0]!]/4U TK3,5DBF6(?PA#EOJ?2K N$50JV\P Z 1F@"2.)(P<9)/5CR3]:
MFJ#[4/\ GC-_W[-'VH?\\9O^_9H R/$.M3Z38/):6,UW-CY5C0FOECX@67CW
MQGK45Y-X;U!EA4H@$)X!.:^O?M*_\\9O^_9H^TC_ )XS?]^S71AZ\J%15(;H
MRJTHU8\LCX0_X0#QK_T+&H_]^31_P@'C7_H6-1_[\FON[[2/^>,W_?LT?:1_
MSQF_[]FO5_MFMV1Q?V?3[L^$?^$ \:_]"QJ/_?DT?\(!XU_Z%C4?^_)K[N^T
MC_GC-_W[-'VD?\\9O^_9H_MFMV0?V?3[L^"KSX>>.);*6./POJ)9AP/)Q7/M
M\*OB,YY\)W^/39_]>OT6^TK_ ,\9O^_9H^T#_GC-_P!^S7%B<?6Q&DM/0Z*.
M&ITOA/@?P3X:^)/@3Q:=8_X0.]U*UN+66QN[1LQ^=#(,, PSM/0@X-;^I:7X
M@U0:+I-U\&]2E\,Z'I<UCI^G27C&599"#Y[RJ!N((^[@"OMK[4/^>,W_ '[-
M'VH?\\9O^_9KSSJ/C73=0^(D.C6#R?"V_F\3:=H3^'K;5C.5B6W;@.8=O,@&
M>=V.>E<OX>T?XP>'=$OM-_L+Q!>*MC)::6DEPWD::\@VO,D9)&_RRZKC&W<3
M7WE]J'_/&;_OV:/M0_YXS?\ ?LT ?*L6A>+O'7AF/2+_ ,"W6FSW$EI)>23W
M#/"6MH?)C\N,J!&".2,G)KV?P/\ "_3?#<"374:RW6!U' KT/[4/^>,W_?LT
M?:A_SQF_[]F@"5555"J, =A3J@^U#_GC-_W[-'VH?\\9O^_9H GHJ#[4/^>,
MW_?LT?:A_P \9O\ OV: )B<#->>>.?%FN6%L]MH>C7=S*>-Z1D@5WOVH?\\9
MO^_9H^U#_GC-_P!^S0!\,ZEX,\<ZCJUW?R^&M1:2XE:5CY)Y))/]:J?\*_\
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MNI+$G)]S6U10!AKX=TU==&L*LHF!WB(2'R@^SR_,"=-VSY<^E;E%% !1110
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M9?+9P2H(9,$D$8..M6;7QI<7FJ?V?%IZ"634A;P$R<2VNUR9QQ_TRD&/8>M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!M<)\1O&T_@C1K6_M[..Y,\_DD2,0!\I.>/I7=UR?C'P7I/C338-/U>
M2X2*"7SE-NX4[L$<Y!XYJZ,HQJ1=17CU,JJDX-0=F87PW^(5SXY;41<6,5L+
M01E?+8G=NW=<_P"[6%#XQ\2?\(/<V;7Q.M30/?V]YY8^2U4.SDC&,J8RG_ T
M-=EX,^'VA^!FO6T>6[D-X$\S[1('QMW8QA1_>-7+?PM8P>%V\/+([1M:2V?V
MDJOFA),YP<>_TX%76E3G4<J:M'H3052,$JCNQ+3Q$>;6:W>2:WTF+4GEW ;]
MVX%<=C\AY]ZY7Q!XLUJ&.?5M)#CS-&LKN.V=EVQM+.0QY&"=I"UTFI>#8[R6
M&2WUS4-/(LQI\_V8I^_B&=H.Y3@@D\K@\FDN/ ^G7-B]G)>7(1M,ATP,A4,J
MQ,660<?>S^''2L3<SO$&M:I'8S+,MSI>H/HE_="&*='2)X]H5B0N2PW @@@#
M)R#QB6;Q5]H\):I?6_VE[.RLQG4;>5 TLP'SK%N!!V]V(QG(YP<:=SX56_A"
MZAJUU<S_ &&YT]YV5%9UF*Y8@* "-HQ@8JO)X)T_[#J.GVMQ/:66HVP@GMXM
MHCW@!?-48^5B!@XX. 2,\T 5M2\;76GZAJ,?_"/W,^G:9<1V]U?+-& F]4(8
M(3N;'F#(J#4/B9H]GXFDTEHXVB@N5M)I3=1+(LA('RPD[W4$C) ['&<5N7WA
M2SOK#6[.2ZG1=8G2>5EQF,JJ* O'3]V.OJ:JOX/1-;DU&QUF\L(9I_M%Q:QQ
MPNDC\9(9T+)G'.TCOTH [&N=\4^(&\/V,-RL2R>8^S#?3-=%6%X@\-V/B2TB
MMM0DG1(GWKY+ '.,=P: ,C1O&']I:1JVHM:J%TZ'SBJ'EL*QQ_X[5?0=/\1Z
MA8Z;XBOO%UPLEU''<RV4<$7V8(P#>6/EW\ XW;L]ZU]!\(Z7X?CNX[-YY4N@
M%D6=@P(&>, #^\:I:?X/DTN6WAL_$VK+I-LP:'3BT91 #PF\IO*=MI;IQ0!'
MI_C9KR[L7DT&\M=)U.0Q6.H/(A$S8)7<@.Y P4[2>O&<9J'1_'%SJ5SI@D\-
MW-G;:JLGV.X>>-A)(BEBI4'*@A3@GTZ"K6G^"+:PO[*3^UK^>PT^0RV6G2LG
MDVS$$#!"AF"AB%#$XS5VR\)V=E;Z!!'=3L-$9VA9MN7W(R'=QZ.>F* .:T7Q
MMX@/A2PO]6\/R3W-Y>?9+?R;B/,[$R<XX"A=@'/7K5R;QIJ%J+C/A6ZG73(E
MDU0Q7$9^RY7?M7)'FL$PQQCJ._%7;+P7#9I;P#5KV6TM+X7UM#)LQ"?G)0$*
M"5)D/4D\#FEU;P?%JE[>7"ZMJ&G0ZBBQW]O;,@2Z 7;R64E3M^4E2,@"@";1
M=0EOO&.NJMPTUDL%G);J3\JAT<D@>_%=56)I^BVFG:M?:A;LP^U1PQ>5QMC6
M)2%V_@U;= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cvm_s3aimg16.jpg
<TEXT>
begin 644 cvm_s3aimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $7 E4# 2(  A$! Q$!_\0
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M6_VOJO\ T$;G_OX:/[7U7_H(W/\ W\-']ET>[_KY!]=J=D?:7_"T/"GKJ/\
MX+YO_B:/^%H>%/74?_!?-_\ $U\6_P!KZK_T$;G_ +^&IOMFO?8/M_VNZ^R^
M;Y'F^:<;]N[;UZXYI?V72[O[T7];J=D?9G_"T/"GKJ/_ (+YO_B:/^%H>%/7
M4?\ P7S?_$U\:6UYKUX9A:W5W,8(6GDVR'Y(UY9CST%0?VOJO_01N?\ OX:/
M[+H]W]Z#ZW4[(^T?^%H^%?[VH_\ @OF_^)I?^%H^%/74?_!?-_\ $U\6_P!K
MZK_T$;G_ +^&KT8\43:-+K$<UU_9\3F-IS-M!88R "<MC(S@'&1FD\LHK=O[
MT3]<JOHC[$_X6AX4]=1_\%\W_P 31_PM#PIZZC_X+YO_ (FOBW^V-4 _Y"-S
M_P!_#4]Y>:]I]]-8WMU=P7,#;)(GD.4/H>:7]FT>[^]%?6ZG9'V5_P +1\*^
MNH_^"^;_ .)H_P"%H^%?74?_  7S?_$U\7?VOJO_ $$;G_OX:D34-<DMIKF.
M[O&A@V^;('8K'N.%R>V2#BG_ &91[L7UNIV1]G?\+0\*?WM1_P#!?-_\31_P
MM#PI_>U'_P %\W_Q-?&EU>:]8S+#=W5W#(T:2A6D.2CJ&5NO0J0?QJ#^U]5_
MZ"-S_P!_#26647U?WH?UNIV1]H_\+1\*^NH_^"^;_P")H_X6CX5]=1_\%\W_
M ,37Q=_:^J_]!&Y_[^&I;>^UR[N%M[6ZO)YGSMCC=F8X!)P/H"?PI_V91[L/
MK=3LC[-_X6AX4]=1_P#!?-_\31_PM#PIZZC_ ."^;_XFOC.SO==U"\AL[*\N
MI[B=ML<:RG+'T'-0?VQJA&1J5S_W\-/^RZ/=_>@^MU.R/M/_ (6AX4]=1_\
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M-'_"T/"G][4?_!?-_P#$U\6_VOJO_01N?^_AH_M?5?\ H(W/_?PT?V51[O\
MKY!]=J=D?:7_  M#PI_>U'_P7S?_ !-'_"T/"G][4?\ P7S?_$U\6_VOJO\
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M:IH4*0?VSY4T-C$Q"P+:[MNW=EE#89N<G!Y&:X^WN;BSN!<6D[P3*&4/&<$
M@J1GW!(_&I;74]2L5B6QOY[98I?/012%=LFW;N&.^WCZ<54J;;NF2I6/0=+L
M4NIKF\2XT./3[S1M1A74;"!X(R45"_F1$9#*&'0<YZFN2\66=IIM[;6FF6ZM
MIXMUFM;WJ]^C<^:Q[<@KL_@VD')R33NM?UR^F,UWJMS,YA:WR7P/+;[R #@
M]QWJD]U<R6D-I).[V\#,T43-E8RV-V!VS@9K&%.47=L<I)JQWEO8Z;#XNT/P
M>OA^VO++4(+8R7I1C<S>=&&>>.3/RJA)P -N(SNSS69KUTJ_#_PO8K;63HK7
MH6Y6 "1ML^-P;MN &?6L.'Q!KUOI+:1;ZQ=Q6#!E-NLI"[3]Y1Z ]P.#WJC)
M<W$EM!;23.\%ON\J,GY8]QRV!VR>35JF[IM[?\$'-6LCJ919Z-X6\/R0Z!::
MH^KI+)//<QL[,PE:/R(B"-A  )(^8EQVP*ZGQ%8Z5:ZKXGURYET^*Z.N/9DZ
ME;R7$=N@C5@-J*1N8DC+=D..<UYS8:]K6EVDUIINJW5I;SG,D<4A56.,9]CC
MC(P:=;^(-<M;Z>^M]6N4N;A0LTF_)E Z;L\-C QGI6;I2;O?^KC4U:QU=U9Z
M/ISW6M6Z:7#I[+;PN;VPGF2*Y="[)#$^#L*@,&?H" ":O:Q#:Z#I'C:ST_3[
M3[/+%I5P$D@9O*,R[B%W_,H!8E0>17#6_B'7;6ZNKJWUBZ2>[(,\AD+&4CH6
MSG)'8]1VI8O$6OP7,MS#K5ZD\T(MY)/.):2,=$)[@=O2J=*7?^M/\A\\>QW<
MK:;J'C+3/#MUHMI+'=Z+;K+=2!FN XL0R.C9^3:57@#GG.<\<?X5M;6>WUC4
MKBR34)M-L/M4-G)DI(QD12[ 8+*BL6([X&>,UEKJ6HK>QWRWTPNHD$<<P<[D
M4+L"@^@7Y?I4=G=W6G7<5YI]S+:7$1S'+"Q5E[<$>U-4FHV3[$N:;N=3:+;Z
MUI>L7TWAVULY(='DFAEMHFCCF=)X@957.T%59@=O'J,UM^#;1-.N?!.HC3HO
MM%^VI[I)HMWFHL>$(SZ?, ?<UQ3^)?$$FKQ:N^M79OXE,<<_F'**1@J.P4Y.
M1C!S3'\0:[)>0WDFL7C7,$IGAE,QW12$ ;E]#A5''8"G[.3O'^MAJ:3N7/"$
M-MK'CS2(;ZS@:VNK@>9;HFV,@J3M"CH/:NATM='@O?!.F2>';"Z&LVT'V^:X
M5F>3S)WCRG(V,  =PY) [#%<6VJ:DVK?VNU],=0W^9]IW?O-V,9S]*8M_?+-
M:3+=RB2R"K;.&Y@"L64+Z8))'N:<Z;EU%&21TG@9(K?XD6L4BM+#%]K5E#;6
M=1!*,9[$@=:MZ990>*-&L9K30=+M+V#54ME6-7CBE@,#RE9<$LVWRB=P^8@D
M<\5QT%Y=6MW]KM[B2&X^;]ZC8;Y@0W/N"0?K3K?4+ZSC2.TO)K=$F6X41.5V
MR*"%<8_B ) /O52I-^\GJ)225F>E^'[?2;^\\,Z]8+8M-%XA@L_-L+*2U1T9
M"^TJV0Q!7@CG#<]JYF:]V_"JTM?L=FX?6+E?-: &08BB.X-V;G&?3BL:X\2>
M(+J1))]:NW9)$F3]X5".I)5@!P",GD>M5KW5=2U$N;^^FN=\IG;S&R#(0%+?
M4A5'X"E&E)2N_P"M_P#,IS5M"G111789!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!],
M_ 7_ ))U=?\ 82E_] CHH^ O_).KK_L)2_\ H$=%?-S^)G9#X4>_T445XI[0
M4444 %%%% !1110 5%/_ ,>TO^Z?Y5+44_\ Q[2_[I_E0!G^'?\ D5M(_P"O
M.'_T 5J5E^'?^16TC_KSA_\ 0!6I1U$MCQS]H7_D0-/_ .PDG_HJ6ODP]37U
MG^T+_P B!I__ &$D_P#14M?,,>O:E#X9N?#:/%_9MQ<K=R*8E+^8  ,/U X'
M'^)KZ'+[^RT[GC8K^([C?#VDC7?$MAHYG^SB[E\OS0N[9P3G'?I46A:?'K5[
M-;"Y$/EV<]UD#=GRHFDV_CMQFM#P7?VNE^/-%U&]N%M[>WN!(\K=$ !Y_/%:
MNB^-M:DDO;?6M:)M9M-NX=LD: -(T#!%RJYY8@5Z,W--\O8YHJ.ESGV\/:\N
MC?VPVDW(L-@D,^W@(>-^.NW_ &L8]ZE;PMXB6QDOCI,QM8H3<22!E(2,#)<X
M.0.176Z;=>&=-NGN+:ZTB.QFTF:W220S/?-,]L5*R#HH\PD=-N,8]:Q+JSL-
M/\*1V>DZUI4GGQI<:E(DQ$]PPY$"*5^ZGIGYGY/ 6N=59-V_0KD1D7?AW7;'
M2QJEYI-S!984F9UX4-]TL.J@]L@9IS^&?$4<]M;OHEXLUU(8H(S$=TK 9(4=
M\#G/2NLGN/#=E9>)X=/NM'6TO],EM]/:)IGNYCN1E$Q/"M\O((^]C;@<U'=>
M(--N_'_B"9M6\NUU/3CIUMJ&&9;?,48'0;@GRLAP. Q.#352;Z?UH')%=3 U
M#PO?:3X;.IZE#-:W/VX6JPNHVLAB+[PP.#R,<<5GQ:+J\^FMJ4.FW$EDJEC<
M*GR !MIY^IQCK6[?_8M/^'B:$NN6E]=IJHNO(M&9XXXS"5RK$ $Y SCID=>T
M3ZAIT_AKPEI=Y>2_9K6[N)+Z&'.Z)'E3Y@.FXH&Q6JE*WS$TBA=>%_$5E]G-
MYH]S;K<2K#&SJ -YZ*>?E;V;!JWKGA>XT'4->L;Q;EWTQE$<T<:^6ZF39O?D
M[ >W4YX-;=Y=:):>&/$UA#/H:O=O;O:1Z<9I&F2.?=EV?C=M/0X;[W3H;EYK
M&AZ?KOBG5DU"SU2WU&\M;^""$L3*BW:R-&P91AMH.14^TF^GX>A7+$XJ]\.:
M_IVGKJ%_H]U;6K;?WLB8"[ON[AU7/;=C/:JVG:7J6KW36VF64MW*JEV6,<(H
M_B8G@#W)KJI)M-TVZ\2ZPWB*VU9=8MIX88(]YGG:5@P:92 $V?>Y)^91MSUK
M-T6:SN_"NK>'I=1@TVXNKB"YCEN25AG6,.#$[ ';RX89&,CG'%)3ERM_U_2)
MY5<DT'P;J.I>(+S3-0M+NU_L^V>ZNHU51-M"Y55#D#+$@ ],'-9$.ESZCK[:
M5I-O-)(TC+&DS*K*%R278':, $DYP ":ZN35M(@MO[*.I17C6?ARYT_[6H;9
M/,\N]8D)&2J@[02 #@XXQ7/^%[VSL]2NX+^?[+;ZA8SV!N=I80&1<*Y Y*Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Z9^ O_ "3JZ_["4O\ Z!'11\!?^2=77_82E_\
M0(Z*^;G\3.R'PH]_HHHKQ3V@HHHH **** "BBB@ J*?_ (]I?]T_RJ6HI_\
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M#>&"A@#@GJ,5[%\3/A[KWC37?"FO>&O%4/A[4_#LEQ-#++9"Z5S*BH?E+ <
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M'D@ 8'\JMUG:7=-?:+97LBA7N((Y6 Z LH/]:T:3W&CQO]H7_D0-/_["2?\
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MXZ7]G,DA!A,_G9W9SOSD;@>^<<8KD=RY"[AD]JLV=E<ZA<-;VD?F2+%),1N
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MY^YZ/=+HD/B?QIJ.AKJ,^O6C7N+>[,:QE'9XYY4V\N45B=IQP<\[2*YB8?\
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M%5/W6 [$XR <X)JQ;^(_#=G+<26MT+>PN--EM(M/CTQ?,@E> H6>8\L-Y)W
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MI.DR))&;BVLY+A7<$J\H!?!'&.>.OXU+KW@W4-+OM9-N('MM.FDWP"Z1[F&
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M_"C_ (1GQ#_T [__ ,!G_P *^_MM&RJ_M>7\GXA]17<^ ?\ A&?$/_0#O_\
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M^7\0^HKN? /_  C/B'_H!W__ (#/_A1_PC/B'_H!W_\ X#/_ (5]^[:-M/\
MM67\OXA]17\Q\!?\(SXA_P"@'?\ _@,_^%'_  C/B'_H!W__ (#/_A7W[MHV
MT?VK+^7\0^HK^8^ O^$9\0_] .__ / 9_P#"C_A&?$/_ $ [_P#\!G_PK[^V
MT;:7]JR_E_$/J*[GP#_PC/B'_H!W_P#X#/\ X4?\(SXA_P"@'?\ _@,_^%??
MVQ?2C8OI5?VK+^3\0^HKN? /_",^(?\ H!W_ /X#/_A1_P (SXA_Z =__P"
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MVA/^2?Z?_P!A)/\ T5+7R9@\G!QG&<<5[F!PU*K3YIQN[GEXFK.%2T6?1O\
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MYF@MMXFE7#)&4 +@L#CC<O?G/&:/JN'>G*A^VJ]V>]_\+WU#_H*Z-_X 3?\
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M;1O_   F_P#CM'_"]K[_ *"VC_\ @!-_\=KP>#PWX@N=)_M:WTBXDLMC2"4
M?,B_>95SN91SE@"!@U#_ &+JW]D?VO\ V?,-/VAOM)7$9!8H,'O\P(QUXJ/J
MN'[(/;5N[/?_ /A>VH?]!;1O_ ";_P".TG_"]]0_Z"NC?^ $W_QVO##X;O/^
M$)3Q0#FW-V]LRY4;555._KD\MC&.V>E17?AKQ!8:8-2O=(N(+3"EI' ^0-]T
ML,Y0'L6 S5?5<*_LH?MJO=GO'_"^+_\ Z"VC?^ $W_QVD_X7MJ'_ $%M&_\
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M\->(-7LS>:9I-Q=0;BJN@'[QAR50$Y<CN%R:7U3#K[*#VU;NSWG_ (7Q?_\
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MHHKS3V0HHHH **** "BBB@ J*?\ X]I?]T_RJ6HI_P#CVE_W3_*@#/\ #O\
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MYH;,&W:-55BH)9FP3@8&U>_3!\.ZLECH#P_VLNGZC_;%I>QS21M)L*1RAI2
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M?:;G3K#1K!F.GVNZ>Y>1"%PG\).&+,V<8[\5AW7C'^TIK]=:T6WO[2[N!=K
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M,6<>6V+F,@=T"R$>N%_O5D:QKG]IV6GZ?!9"SL=/$GDQ&9YFRY!8EVYQP,
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M/M&6V#.6P.3CH* -.H9O^/:7_=/\JFK*U6\ATW39;B9OX2J(.6D<_=11W)/
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MT<J3.I5P .C*VW##()]JH?\ "&WY?2K>.^LGO=4ACN(+42$.L+H7,DAQM15
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M5?NM%UFRN(+>\TF\MYK@XA26!E:4^B@CD\C@4D>CZO-=0VL.E7CW$\?G1Q+
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M &$I?_0(Z*/@+_R3JZ_["4O_ *!'17S<_B9V0^%'O]%%%>*>T%%%% !1110
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M\/+U68!AJ4F1Z?NXZ*^?G4]YG?#X4>]4445Y!ZX4444 %%%% !1110 4444
M5+JQM+Z/R;RUBN(^NV5 XS^-+;V\%I:)#:Q)#"@PJH,!1["BB@"I>:?8ZA"(
M]0LH+N('S D\:R*#ZX(Z\FJW_")^&?\ H7=+_P# ./\ PHHK.-27<EQ0[_A%
M/#/_ $+VF?\ @''_ (4?\(IX9_Z%[3/_  #C_P ***T]I+N')'L'_"*>&?\
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M]IG_ (!Q_P"%'_"*>&?^A>TS_P  X_\ "BBK]I+N')'L'_"*>&?^A>TS_P
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M4>TEW#DCV#_A%/#/_0O:9_X!Q_X4?\(IX9_Z%[3/_ ./_"BBCVDNX<D>P?\
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2W8W".U5,XZ9P.:***=V.R/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cvm_s3aimg15.jpg
<TEXT>
begin 644 cvm_s3aimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& =4# 2(  A$! Q$!_\0
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M2M:Z3)****DU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5RQ'WL#.W^55R2[![2/='<T445!J%%%% !1110 4444 %%%% !1110 4444
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M#'X%\-I +;["SQK+#*OF3.Y7R3F)02<A5R0%Z8)]:^3_ /A87CS_ *&S4_\
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MI47AG3_-$_B+7)IH?[.5DQ;E)#'AFSUR#D]!CKQ66OCGQ(OB6[\0--:RW=Y
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M444 %%%% !1110!4DM[>1]\D*._'S,H)X.1^1YJ:2..:,QRQJZ'JK#(-2T4
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MD<D8DC(96Z$5V4LFP]1:-W]?^ >#B\RQ&%E:233V=CZR_P"%^> O^>E]_P"
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MU.U_Z[G.I)6NCWN'X<^!+73=5-K=1WS75OLCN+K4(%%@[/;E(^F3)MD<^9T
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M+$8Y(P:IT=!@45V)65B6%%%%,04444 %%%% !1110 4444 %:VC?:_./E_\
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M20.<! J[FYZ9"D$C.0#FJ@Y0?-'1B=GN>6?\,O\ PW_Y[:S_ .!@_P#B:/\
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M_P")KUB.021B1<[6 (R"#^1J:E]=Q'\[^\G^SL-_(CR'_AGOP/\ \]M2_P#
MD?\ Q-'_  SWX'_Y[:E_X$C_ .)KUZBE]=Q'\[^\/[/PW\B/(?\ AGOP/_SV
MU+_P)'_Q-'_#/?@?_GMJ7_@2/_B:]>HH^NXC^=_>']GX;^1'D/\ PSWX'_Y[
M:E_X$C_XFC_AGOP/_P ]M2_\"1_\37KU%'UW$?SO[P_L_#?R(\A_X9[\#_\
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MBN>)?^_=K_\ &J:?AWXMS\OQ?\1@>\%J?_:5'+'^9?C_ )!=]CTBBO.1\/\
MQ@!_R5[Q!^-K:'_VE1_PK_QC_P!%>U__ ,!;3_XU1RQ_F7X_Y!=]CT>BO./^
M%?\ C+_HKVO_ /@+:?\ QJFM\/\ QK_!\8-= ][.T/\ [3HY(_S+\?\ (5WV
M/2:*\ZC\"^-XTV_\+:U9^<Y>PM2?_0*D_P"$)\<?]%8U/_P76O\ \11R1_F7
MX_Y!=]CT&BO/?^$)\<?]%8U/_P %UK_\13)/!/CP@>7\6M24_P"UIMJ?_911
MRQ_F7X_Y!=]CT:BO.D\&?$!,_P#%VKUO][2;8_TI_P#PB'Q _P"BL7?_ (*+
M;_"IY8_S+\?\AW)?%'AW5;Z>_FTTV\L>IP0VMU'*Q61$1V.Z,]"=KMP<#(!S
M6E8Z7JT.J:EJ%^MI-<W"F*W=9&VQQ G9&5*\#G+$$DD^@&,?_A#_ (@_]%7N
MO_!1;?X5S/C;P;\3IO VL1:;\0KO5+EK9@MHMA! 9_[R!UP5)&0,=ZTBHNT>
M9?B2WUL:<>@ZAK%K-]GU#3;C49H[FUU&:.X:0'SU16<87Y2@C"JAXP!SWK0O
M_"&J:G]KDOC:2R^?"UL/-<(88GW)"P"Y7/+,P));'& !7S;\$?!/Q 7XB^?I
M\.I>&K:&*2.\O)K3:N,<1[)  Y+8]<8)KZ=/A?QQ_P!%)N!_W#+?_"JJ04)<
MO,OQ,O:2Z1;^XZ'0;.ZTW0+.QN;AKJ:",(TI).X_CS@=.>>*V*X%?"WQ!5O^
M2F,?8Z1!_C3_ /A&?B#_ -%(_P#*1#_C4.$6_B7X_P"0O:R_D?X'=T5P7_",
M_$+_ **1_P"4B'_&@^&?B%CY?B1S[Z1#_C3Y(_S+\?\ (?M9?R,[ZBN 'AKX
MB?\ 11D/UT>+_P"*I?\ A&_B)_T4:/\ \$\7_P 51R1_F7X_Y"]K+^5G>T5P
M?_"-?$3_ **1'_X)XO\ XJD;PU\2,_+\2(L>^CQ?_%4O9Q_F7X_Y#]I+^1_A
M_F=Y_P !H_X#7#+H'Q&50&\?6KGU.D+G]'J3^P?B)_T/EG_X)U_^.5/LU_,O
MQ#VDOY7^!V]%<-_8/Q&_Z'RS_P#!.O\ \<J)M#^)FX[?'FGX[9T<9_\ 1E7R
M+^9?C_D/VK_E9WO-'-<-_8_Q,_Z'33/_  4G_P".4O\ 8_Q*_P"ARTS_ ,%)
M_P#CE+V<?YE^/^0>T?\ *_P.YHKA?['^)?\ T.6E_P#@J/\ \<J,:1\4\\^+
M]%/L=+;_ ..4_91_F7X_Y"]K+^1_A_F=]17"?V7\4O\ H:M#_P#!7)_\=I/[
M+^*7_0U:'_X*Y/\ X[2]G'^9?C_D'M9?R/\ #_,[RBN#.F_%/'R^*-")]]-D
M'_M2D_LWXJ=_$N@M_P!PZ3_XY3]G'^9?C_D+VTOY'^'^9V7VB'[1]G\Y/.QN
MV;ANQZXJU7Q?+H'Q _X665:RU ^(/MF\7*HV,[L[P_39CGKC%?92[MH#?>QV
MJ\1AXT>7EDI770RPV)E6YN:+C9VU+%%%%<QW!1110 4444 %%%% #:X?Q)XP
MFT/Q;I'A^"UM'DU&-I!+=W+Q#AT3:H2-\L=^>=HXZUW%<WJGA?3-6U2UU2XD
MO(KRV0Q)):7DMN2A8,5;8PW#*C@YZ546D_>V$]F9EO\ $;PS=&'R&O6>>2..
M%/LDFZ7S Y5E&.5_=R?-T&TUE:W\4M+L]-%YI-K)?-\[;)@T&^+R)94E3*_,
MC^20&'O716?@OP[8W-E<6NGM')9+&D!\UR%""0*,$\\32=?7V%4F^&_A%K5[
M62PD>)OE >YD)1/+>,1J2WRH%E<!1P-U6G2OLQ:D?_"S/#:W @F^V(P?8\GV
M20Q*1((G._&-JNRJ3_M"DC^*7A&:.=[>ZN;DQ3&()%;.[281WWJ .5Q%(<_[
M)]JTF\#>&6C>-M+)5_,W#SGYWS+,W?NZ*?PQTJ&'P/X9MXECALYO*69YHXS<
M2%(B\;QL$!;"KMD?@<<_2B].VS'J4KKXAVR>%?$/B"QTR::+1V"IYS>6ET"B
M.&5L$A<2#J,^U5['XJ:&;>T76%%G=7%W):JMNYGB.QU0RA]JG9N=5R5!R>F.
M:V%\%^'1H^HZ/]EE6SU!(X[B$7$F#L144K\WRG:JY(P3@$TVW\!>&[6:VN8;
M6X^U6\S3BY:[E::5FV[O,<MF0'8G#$CY14IT^J9/O%*3XD:!YJ"WDE*>8-TD
MT,D:O$1)^\C.T[QF)\= <=>F9(/B)X;N;BV@CDO!+<3>2L36L@<95&#$8S@K
M(A'LV>QQ1L/ACH]K?WT^H3/>P386WME+QQVJ RG:OSD_\MGX&!Z 5L3> ?#,
M[CS+*4J)8IF03R!7:-$1,C.#@1)^7N<U[GF/WCL****R*"BBB@ HHHH ****
M "BBB@ HHHH **** ,'Q'KEKX;\/7FN7L4LL%HH9DAV[VR0 !N('4CJ0*S8?
M&FDMI?VJ\8V4P56^RR2Q22'<7"8,;,AW&-L8;MVK1\1:';^(O#]UHE](ZV]T
M%60IC. P;'((YQCI6!J7@'2-1U*&X@N9].@C6)6LK18TA?RV<H<;21@R/]T@
M'//2KCRV][<3OT%C^(6DMX5OO$BV=XUO9O!&T6$#NTJ1,N,L%'^N4$D@#!K1
ML_&6BS36T-]=1:;>W*>8EI<3Q-)M^;!S&S*00C$88]#Z5F+\.]);PA?>'4O[
MH07SP2-*PC=E,21*N 5*D$0J2""#DTG_  K?3FB"76I74K_Z."R1PPC$)E*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I/8\T4
M4 92Z)I"WT-TNG6ZW$"LD;B,#8"03CTY _*DL-+TS3;6.SL;&&W@B78B(@
MZ?R HHJ@)A9V<<26JVL*Q[&C"+& H7NN/0^E/_L^S\KR_LD/EE=A38,8SG&,
M=,\T44 +]GM5#1K;Q@;?+("#!7^[].>E,^QVOF[?L\6.?X!WSG^9_,T44 2+
M968B2U6VA$<?W4\L;5^@[=:C"6L;C; H/8A1QU/\R?SHHI %K;VD94V]O'%P
M2-B!< G)''OS6A112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_s3aimg14.jpg
<TEXT>
begin 644 cvm_s3aimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %! 5,# 2(  A$! Q$!_\0
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M-QU !'S&N6N&^-5SY&M+>ZU;7%I8:#,VGPVT/DW=Q(V+]7!4D;5))"D8_ 4
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M1NVX#;+'(NY)$()#(<,,^JL.U;M !1110 4444 %%%% !1110 4444 %%%%
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M/D?+R(D0+ 8+=,X%9GC?XL>(M*\-:+=Z1;6]EJ#VTCZC%<V4UP(KU;6*>*P
M4J0\IEVAN<;2,$\4 >ZT5\\7WQ6\?1ZUXGL[>QT^*33X+J3[)=6\D9TY8I8%
MBDEE+!)?.221E4;1E ,XR1Z?\-?$&M>*OA_I^M:]8?8[VX:4 >48O-C61ECE
MV$MMWH%;&2.>"1B@#N**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J.218P,Y)/11U-1-(6)CB 9^Y/1?K_A2I&J$L27<]6/7_ZPH 11<L,^8L?^
MSMW8_'-/\NX_Y[I_W[_^O4U% $/EW'_/=/\ OW_]>CR[C_GNG_?O_P"O4U%
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MW_\ 7H\NX_Y[I_W[_P#KU-12&0^7<?\ /=/^_?\ ]>CR[C_GNG_?O_Z]344
M0^7<?\]T_P"_?_UZD&=HW')[FG44 %%%% !1110 5D?V]HNZYQJUJ?L@+3_O
M5_= '!+>G/%:]<'=:3J&H:M>7=WI<C6S6;6OV<W2@N2ZD>25QL!"DG<1D[>F
M,T =)'KFCR) \>IVQ6XD\N$^8/WC<<#U/(_,5=MYHYE+PR*ZABA*G(!!P1^!
M!%<?_P ([JEUI;374EP+R.5Q:QR7"NR1%T95E;!W;60/P<X 7)J]X=L-:TZ^
MNH;IF.GH-L 9E;/SMAEP,CY-N[=R6R?J =82 "3P!W-5BSS_ .KRD?\ >[M]
M/3ZU,\:R8WC('..U24 -1%C0*BX [4ZBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /G+X]:_K*ZA;>&;>_:VT^:U$TZQ<-,2[#:Q_N_*./SS
MQ7@G]E0_\]7_ $KVWX]_\CW9?]>*?^C)*\BK[S)J-/V,7R[GR.-J3]M)7,_^
MR8?^>C_I1_9,/_/1_P!*T**^E]E#L<//+N8][81VUC+.DC%D&1G&.M<Z26.2
M<FNMU7_D$W'^Z/YBN1KS,8E&:4>QV4&W&[/MC]GW_DBVF?\ 7>X_]&M7K/:O
M*/V>_P#DBFE_]=[C_P!&M7J_:OSG$_QI>K/JJ/\ #CZ%2T_X^[W_ *ZK_P"B
MUJ[5*T_X^[W_ *ZK_P"BUJ[7.:H****!A1110 4444 %%%% !1110 4444 %
M%%% !1136944L[!5'<T .JL9&8E(>W!<]!_B:9^\F^]F.+TZ,WU]!5H *H50
M !T H A^RP_Q1AV[L_)-+]EMO^>"?]\U/10!!]EMO^>"?]\T?9;;_G@G_?-3
MT4 0?9;;_G@G_?-'V6V_YX)_WS4]% $'V6V_YX)_WS1]EMO^>"?]\U/10!!]
MEMO^>"?]\T?9;;_G@G_?-3T4 0?9;;_G@G_?-'V6V_YX)_WS4]% $'V6V_YX
M)_WS1]EMO^>"?]\U/10!!]EMO^>"?]\T?9;;_G@G_?-3T4 ?,'QZC6/QU:B-
M H^P)T&/^6DE>35ZW\?/^1\M/^O)/_1DE>25]_DW\*/H?&8W^-+U"BBBOHN8
MY"EJO_()N/\ ='\Q7(UUVJ_\@FX_W1_,5R->7C?C7H=V'^%GVM^S_!"_P6TP
MO&K'S[CDC_IJU>J?9;?_ )XI_P!\UY;^S[_R1;3/^N]Q_P"C6KUGTK\ZQ/\
M&EZL^JH_PX^A0M;>W^UWW[E/]:O\/_3-:M?9;;_G@G_?-0VG_'W>_P#75?\
MT6M7:P9JB#[+;?\ /!/^^:/LMM_SP3_OFIZ*0R#[+;?\\$_[YH^RVW_/!/\
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M+8TQW3?*G9/7Z_X4Z.+YO,D;>_KV'TJ>@ HHHH **** "BBB@ HHHH ****
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M(5=4/_$KG^@_F*Y6NHU,_P#$KG^@_F*Y6O+QGQKT.VA\)]Q?L[G_ (LEI?\
MUWN/_1K5ZQZ5Y'^SW#"_P2TLM$C'S[CDJ#_RU:O5OL]O_P \(_\ OD5^?XC^
M-+U9]-1_AQ]".U/^EWW_ %U7_P!%K5VLVUM[?[7??N(_]:O\(_YYK5W[-;_\
M^\?_ 'R*Q9HB6BHOLUO_ ,^\?_?(H^S6_P#S[Q_]\BD,EHJ+[-;_ //O'_WR
M*/LUO_S[Q_\ ?(H EHJ'[/;_ //"/_OD5( % "C '84 .HHHH *Q]>^V?\(Y
M??81FX\EMH.P@^OW_EZ9^]QZUL5A>)EM6\,ZBM[YWV<Q'=Y(!?VP#P><=>/7
MB@"CX5FAN+&>:W>ZEBW*@>=[9QP,84P<<#'!]L5U=<CX862&\U+[<DJ:FWE>
M>K1QHH3!V%1&2#_%DDYX] *ED\0:@J>($AT@O<:5M$,8DWFXW+N!PH)'TY-
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M06VZ>3=,FZ(KM//FC<)8P&.,/G/%;7AO5[RZO;S2[R$F6U):2;>6.\R,"I!
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M&C[*G*]O/S(2FZG/-6N+X-/_ !7_ (=_["5M_P"C5K]%5^Z/I7YS^#3_ ,7
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MT.]$/ES_ //Q_P"."CRY_P#GX_\ '!4U% R'RY_^?C_QP4>7/_S\?^."IJ*
M(?+G_P"?C_QP4>7/_P _'_C@J:B@#Y0_:,#+\0=/#MO/]FISC'_+62O&<U[1
M^TA_R433O^P:G_HV2O%<U]YE7^[Q]#Y;%_QI#LT9IN:,UZIRFUX7/_%56'^^
M?_037JAVDY*@FO*/#1QXGL?]X_\ H)KU#?7QV<_Q(^GZGOY?\#]?T)_E_NBC
MY?[HJ#?1OKY\]0G&U>@ KS?6V_XGU[_UU->@[Z\XUIO^)[>_]=30!Z/\!]S?
M%!0K[3]DE[9]*^JO+G_Y^/\ QP5\I_ (Y^*:_P#7I+_2OK*@"'RY_P#GX_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!.U,:BBLI?$)[$E%%%:C"BBB@ HHHH **** "BBB@ HHHH ***
@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_s3aimg13.jpg
<TEXT>
begin 644 cvm_s3aimg13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" '; ?8# 2(  A$! Q$!_\0
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M$?P_T>'PCJ3^"K>P\;1Z;?I'=?;[-7?!W0S,0# /^>?3GK7=^*/C!KFAZ?\
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M9JFIQ_VUKS1Z=8^ 9=1T:2*],:/?JZKYB%6 >08  Y[\4 ?6M%<[X/N=0O/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI;>Q(X.201P>.*ZZB@#D8O /A&%[TQZ3\EW#-;R1-<2F)8Y3F540MMC#'KL
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MM+9NAW,&AED,LB$$]"[%O7TKK** .-3X?^%X['[+'8W"GSQ<BX^W3_:!($V
MB;?YG"_+C=C'%267@^SL/$&FW]F%AL=)L'L[*S53B(NP+ODGDD(H_,YYKKJ*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #_^(?\ PH+[_P"/5UM% ')?\*^T/_G_ /$/_A07W_QZC_A7VA_\_P#XA_\
M"@OO_CU=;10!R7_"OM#_ .?_ ,0_^%!??_'J/^%?:'_S_P#B'_PH+[_X]76T
M4 <E_P *^T/_ )__ !#_ .%!??\ QZC_ (5]H?\ S_\ B'_PH+[_ ./5UM%
M')?\*^T/_G_\0_\ A07W_P >H_X5]H?_ #_^(?\ PH+[_P"/5UM% ')?\*^T
M/_G_ /$/_A07W_QZC_A7VA_\_P#XA_\ "@OO_CU=;10!R7_"OM#_ .?_ ,0_
M^%!??_'J/^%?:'_S_P#B'_PH+[_X]76T4 <E_P *^T/_ )__ !#_ .%!??\
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M@51U)\07P _\C4I\ Z"" =0U\$],^(+[G_R-6)\<FV? ?Q@=Y3_02-RG! +
M=:\7FT/QQH?CGP7_ ,)=K0NK>VL=1TW2_+DR9[9+-G$\O_31LJI_ZYY[T ?0
M(\!>'R5 U+7R6Y'_ !4-]S_Y&IS> =!52S:AX@ '))\07W'_ )&KP7X(WFNR
M1G[0UK-XO_L"T/AV._G=;633>-[*5!/F>9NWG!/W.U3ZI>>,KGX9>!?^%KLE
MOH4^M1IK$JS2J[V^V7:+K*KL4R",'!P1C- 'N(\!^'RJL-2U\AONG_A(;[!_
M\C4B> _#LA(CU/7G([+XAOC_ .UJ\1DN?!=KJGA-/ ^HW3^'(O%\BN99&:U3
M%HYD6V8]8ASG&0&SBH?A*VAWUYXN\7_#>708-:U!3;Z7H<EXZ_9[&-L&615W
M,))&&[IQ\HXR: /=7\ ^'XUW2:EKZ+ZMXAO@/_1U#^ _#\:AI-2U] 3C+>(;
MX?\ M:O ?$P\0ZE\/O 4GQ,U?1;'4D\R2&RUEK@6FI_N/F6[D 7RIE^\O49Z
M5!8:EX-\0:EX3F^(T5QI'@Q_";2:7;:M>R-&MRLQ$A\TD&201@%2>=N"!0!]
M"OX#\/QKNDU+7T&<9;Q#?#_VM3_^%?:'_P __B'_ ,*"^_\ CU?-?AR?3=0_
MX1"/XW7DD?A__A&)9--;4YGBCDE%RXW,<C,HMQ$1GYL$D<U]*?#V33Y/ASH4
MFEW&I7%@;5?L\NJY^TO'_"9,\YQCKVQ0 ?\ "OM#_P"?_P 0_P#A07W_ ,>H
M_P"%?:'_ ,__ (A_\*"^_P#CU=;10!QX\!^'V=D74M?++U4>(;[(_P#(U"^
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MX_\ C%'VCXG?] CPO_X,;C_XQ7844 <?]H^)W_0(\+_^#&X_^,4?:/B=_P!
MCPO_ .#&X_\ C%=A10!Q_P!H^)W_ $"/"_\ X,;C_P",4?:/B=_T"/"__@QN
M/_C%=A10!Q_VCXG?] CPO_X,;C_XQ1]H^)W_ $"/"_\ X,;C_P",5V%% ''_
M &CXG?\ 0(\+_P#@QN/_ (Q1]H^)W_0(\+_^#&X_^,5V%% ''_:/B=_T"/"_
M_@QN/_C%'VCXG?\ 0(\+_P#@QN/_ (Q7844 <?\ :/B=_P! CPO_ .#&X_\
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M_@QN/_C%'VCXG?\ 0(\+_P#@QN/_ (Q7844 <?\ :/B=_P! CPO_ .#&X_\
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M6L?$S4--T/2Y(=4L9)9Y[J&ZNY=.N%,#Q)O$)MO]8K'@$G@?B*Z?4O%NJ1>
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M^^,#..QK:;XJ:!;V4UU?6MY:?9[@6LR#9+LE9 \291B"9,A5P?O?*<4 :?\
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MU)*I*JG#@9;\"1TJC=?%C5H?#MA=EM-@6>\N[8ZB\,SQ2B!<J5A7]XI?!'/
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M7@7_ *#A_P# 6;_XBC_A:7@7_H.'_P !9O\ XBNSHH XS_A:7@7_ *#A_P#
M6;_XBC_A:7@7_H.'_P !9O\ XBNSHH XS_A:7@7_ *#A_P# 6;_XBC_A:7@7
M_H.'_P !9O\ XBNSHH XS_A:7@7_ *#A_P# 6;_XBC_A:7@7_H.'_P !9O\
MXBNSHH XS_A:7@7_ *#A_P# 6;_XBC_A:7@7_H.'_P !9O\ XBNSHH XS_A:
M7@7_ *#A_P# 6;_XBC_A:7@7_H.'_P !9O\ XBNSHH XS_A:7@7_ *#A_P#
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MP_\ @+-_\161K?CSP+K6B7>DMXFN+1;R)H6FM[682*K<':3&<'&1GMFO2J*
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M1 64$^I% ',>&O%WP_\ #>G36\?B6XO+BZG>ZN;J:TE#32-U.%C"J
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MEH?+*D[-FP<MZ_-T[UVG@G0M2\,^$[;0=0NEN_L+20V\P8LSP!CY6_('S!2
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M.1Q3_$WACQAXBU"SCEBTA4M[BWN[34%FD6;3'789E5-N)=VU@I)7 ;D<5?\
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M+'  RQP*[:O.-+\#_"[6K!;[2]#TZ]MI"0LL+LRY!P1UX(/4=JU?^%6_#_\
MZ%>T_P#'O\: .RHKC?\ A5OP_P#^A7M/_'O\:%^%_P /U8,OA>T!'(/S?XT
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M?]%*U?\ \ K'_P",4 =?17(?\(OXH_Z*5J__ (!6/_QBC_A%_%'_ $4K5_\
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M?77]IV&V>66W06L^P6/V;]W$\A;RE /48WAQ^->B_P#"+^*/^BE:O_X!6/\
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MV\KG3$$EP@296WJI!W8QD@ G&< T[_A%_%'_ $4K5_\ P"L?_C%'_"+^*/\
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M(*[GA')R& [^U>N_9?B5_P!![PS_ ."FX_\ DFC[+\2O^@]X9_\ !3<?_)-
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MU^;2XWU)&5Q*6;!=1A7*9VE@. Q&1V- 'FC:EXQD^ 6KZK-XA,&NW6H,D-]
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MI/YJ*0@7Y3&0Q'S<@XY-37GQ06Q\RQO='2UUA=1?3_L\UXHB^6 3[S+C&-C
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M=NTJ%X V\=>O-,M_ACX=M;RWN+=KZ&&WEMIUM$N"(3) H6-R,9)"@ \X..E
M&KX/UB\U:QU&+4&$EWIVHW%C)(%"B38V5; Z?*RUU5<YX6T.70K"[6ZD26[O
MKV>^N&CSMWR/G SV"[1^%='0 4444 %!X%%% 'D'@GQYJWB+7M.FO[[[/9ZN
M+AK:SDTYXD(C8[5BGS\[!1E@P .3MZ5M>,;KQ9I^N:9#HGB*%)-5O([>"P>P
M5PJ+\TSE]V<! QZ=2!5NW^&^AVVH/<PWFI*BK.+6 71$=@TV?,> 8RC')P<G
M&3C%;47A[3XM:MM8D>>XO+6S^PQ/-*7VH2"S8_OL57+=3@4 =!1110 4444
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ME_\ "?O?_C5 '6T5R7_"?Z5_T!O$O_A/WO\ \:H_X3_2O^@-XE_\)^]_^-4
M=;17)?\ "?Z5_P! ;Q+_ .$_>_\ QJC_ (3_ $K_ * WB7_PG[W_ .-4 =;1
M7)?\)_I7_0&\2_\ A/WO_P :H_X3_2O^@-XE_P#"?O?_ (U0!UM%<E_PG^E?
M] ;Q+_X3][_\:H_X3_2O^@-XE_\ "?O?_C5 '6T5R7_"?Z5_T!O$O_A/WO\
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M0D@$#Q[4&X[1E\\D\"@"W'\0]+N)='>WC;[)?:2VL37!.?LL/RA<@ EB68C
M_NFNBT?7--\06DMUI<YE2*5H9 T;(\<B]596 ((R*\PL/!L>EZ5XGAT_QM91
M7-_*B::ZR!/L5HLQE%N2K;N2\BEEP0",<BNG\$V=CX9M-4CO?$&ES2ZA?O>X
M@G^6,,JC;EV+-]WJ?6@#T&BL_P#MS1?^@Q9?^!"?XT?VYHO_ $&++_P(3_&@
M#0HK/_MS1?\ H,67_@0G^-']N:+_ -!BR_\  A/\: -"BL_^W-%_Z#%E_P"!
M"?XT?VYHO_08LO\ P(3_ !H T**S_P"W-%_Z#%E_X$)_C1_;FB_]!BR_\"$_
MQH T**S_ .W-%_Z#%E_X$)_C1_;FB_\ 08LO_ A/\: -"BL_^W-%_P"@Q9?^
M!"?XT?VYHO\ T&++_P "$_QH T**S_[<T7_H,67_ ($)_C1_;FB_]!BR_P#
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M>!_^A-T/_P %T/\ \31_P@G@?_H3=#_\%T/_ ,37144 <[_P@G@?_H3=#_\
M!=#_ /$T?\()X'_Z$W0__!=#_P#$UT5% '._\()X'_Z$W0__  70_P#Q-'_"
M">!_^A-T/_P70_\ Q-=%10!SO_"">!_^A-T/_P %T/\ \31_P@G@?_H3=#_\
M%T/_ ,37144 <[_P@G@?_H3=#_\ !=#_ /$T?\()X'_Z$W0__!=#_P#$UT5%
M '._\()X'_Z$W0__  70_P#Q-'_"">!_^A-T/_P70_\ Q-=%10!SO_"">!_^
MA-T/_P %T/\ \31_P@G@?_H3=#_\%T/_ ,37144 <[_P@G@?_H3=#_\ !=#_
M /$T?\()X'_Z$W0__!=#_P#$UT5% '._\()X'_Z$W0__  70_P#Q-'_"">!_
M^A-T/_P70_\ Q-=%10!SO_"">!_^A-T/_P %T/\ \31_P@G@?_H3=#_\%T/_
M ,37144 <[_P@G@?_H3=#_\ !=#_ /$T?\()X'_Z$W0__!=#_P#$UT5% '._
M\(+X(_Z$W0__  7P_P#Q-'_"">!_^A-T/_P70_\ Q-=%10!SO_"">!_^A-T/
M_P %T/\ \31_P@G@?_H3=#_\%T/_ ,37144 <[_P@G@?_H3=#_\ !=#_ /$T
M?\()X'_Z$W0__!=#_P#$UT5% '._\()X'_Z$W0__  70_P#Q-'_"">!_^A-T
M/_P70_\ Q-=%10!SO_"">!_^A-T/_P %T/\ \31_P@G@?_H3=#_\%T/_ ,37
M144 <[_P@G@?_H3=#_\ !=#_ /$T?\()X'_Z$W0__!=#_P#$UT5% '._\()X
M'_Z$W0__  70_P#Q-'_"">!_^A-T/_P70_\ Q-=%10!SO_"">!_^A-T/_P %
MT/\ \31_P@G@?_H3=#_\%T/_ ,37144 <[_P@G@?_H3=#_\ !=#_ /$T?\()
MX'_Z$W0__!=#_P#$UT5% '._\()X'_Z$W0__  70_P#Q-'_"">!_^A-T/_P7
M0_\ Q-=%10!SO_"">!_^A-T/_P %T/\ \31_P@G@?_H3=#_\%T/_ ,37144
M<[_P@G@?_H3=#_\ !=#_ /$T?\()X'_Z$W0__!=#_P#$UT5% '._\()X'_Z$
MW0__  70_P#Q-'_"">!_^A-T/_P70_\ Q-=%10!SO_"">!_^A-T/_P %T/\
M\31_P@G@?_H3=#_\%T/_ ,37144 <[_P@G@?_H3=#_\ !=#_ /$T?\()X'_Z
M$W0__!=#_P#$UT5% '._\()X'_Z$W0__  70_P#Q-'_"">!_^A-T/_P70_\
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M9'C9MPVJ<8! SG\J]"U'P7X3U:6WEU+P[8W;V\/V:,RPAML6,;/=?8\5E_\
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M/MV?8?)7R<9SC9C&,\UG0^!?!\&CWFCP^&[!+"\D$MQ"(1B5QT8]\C QZ=J
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M5;@X.#G&*MK\-O%%O8Z?&FJ6-T2U[-?V[R300^?<2B3S$\OYG"<J$8@'KP:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_s3aimg12.jpg
<TEXT>
begin 644 cvm_s3aimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
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MR P]JM5-FG9@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_K5WM6/;R26^MSVLFTI.#.C!N>, @BEL1LS:HHHIEA1110 TKD8-4O[(TO\
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M_3.?6JC4E"ZCL1*C1F[R;^[_ ()B'X?^'TU&ZO56V2XO5\N:3RUWSJ/X6/\
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M'_\ A.O!OA&>1M<\1V>F:EXHOH]4U&WTM;BZM8T+;)$3821,Y&YL,!@;0,T
M?8-%?-VCZK\6/$$GPXTNZU_5='343JK7E\-/C6:>WA:,VK2JRE8G=<YZ=3QF
MOI'MZT %%%% !1110!7FMX+A0MQ"DH!R Z@XK+2SNK6\N)-/@MA!-M.TDIM(
M&#P!6Y2<4FKB:N9OF:Q_SQM?^_C?X51TW4-5%RUOK=O:6\C!GC,$I8%0P SD
M#GFM^H)K6VN-OVBWCEV]-Z@XI6?<5GT8[[3;_P#/:/\ [Z%'VFW_ .>T?_?0
MJ'^R]/\ ^?*#_OV*/[+T_P#Y\H/^_8IZAJ)'?6<Q<1W4+E#M;;(#@^AJV&#*
M,<@]Q6;#H.CVYE:WTVVC,S;W*QCYF]:ALX-4LK..UCCM72/(4EV'&>.U*[ZA
M=]3;Q163)-JT<3R&&T(52V/,;M^%7;6;[39PW&W;YB!L=<9%.XT[EFBBBF,*
M*** "BBB@ HHHH **** "BBB@ HHHH X?7]!TRXUK2I)]/MII);C#O)"K%OW
M;=21S760PQP0K'#&J1J,*JC  ] *R]:_Y"VC_P#7R?\ T6U;6.:B*2DSIJSE
M*$$WI9_F344459S'(W>@^('U6^NM/\3&SBN6C98OLJOY97AN3ZBIQH_B7^W?
MM9\5$V6S;]F^R)U]<UTU%7[27EM;9"LCGK_3-?N+8)9^)#:R!U;?]E1L@'D?
MC56]T;Q1/=F2U\6FVBVJ/+^R(>0<DY]Q75T4U5DNB^Y?Y!8Y&ZT/Q9+#>K#X
MN,+RN&A;[&A\I1U'XT^#1O%$<%XDWBXRR2@"%_L:#RCC&<=^:ZNBG[:5K67W
M+_(+&);Z?K4=K''-KGFRJH#/]G4;CZU/]BU7_H,?^2ZUJ8I:CVDGT7W(+&':
MV.L0ZTUU<:U]HLC%M%KY"KAL_>W"MNBBI=V[C%HHHH **** "BBB@ HHHH *
M*** "BBB@ K&\/?\>EW_ -?DW_H5;-8WA[_CTN_^OR;_ -"H V:*** "BBB@
M HHHH **** "N ^)$<TNB6,4,+W7^FHTELL;2K,@!R'13N9>A./:N_KSGQAX
M3U_5/$T6L:.-,>2.*)8I+R21'MF23>2FT'[PX- '1>#;1K'P?86[SW$Q52<W
M$;1LN6)V[6Y '09[ 5TE4=/:^:QC;4HX8KLC]XL#%D!]B0":O4 %>*WGC[Q5
M%XAUBRDN(;"WCNFBCD:W$BVD:]&?G.7.  ?7BO:JKM#"V_=$IWXW9 ^;'3-
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M4W*46G9;/34]/$TJ,:-.I"2<I)W2OIKH;X;<H8=Z6LU;C5%4#^RTX'_/P/\
M"E^TZE_T#5_\"!_A72>7<T:*YJ;5/%"7YCA\.Q26VY!YIO #@_>.,=JLV]]K
MDEQ<K<:+'%$C 1.+H'S!CKTXI\R W:*Q[F\UB.TEDM])2695)1#< ;CV&<5!
MIVJ:I+'8QZMI:V,]RIW*DPD",!G'2ES(=];&_1115#"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *QO#W_'I=_]?DW_ *%6S6-X>_X]+O\ Z_)O
M_0J -FBBB@ HHHH **** "BBB@ HHHH **** "N-NOA[X4NKRZOO[)2UN[K'
MF3VI,3DAB<Y7N<G)[YKLJ* .>URTMK7PI+;V\*1Q0QI'&H'W5!& *Z'M6/XD
M_P"1;N_H/_0A53Q9KTGAKP5JWB"'3YM1FL;=IH[6W0N\S@?*H YY./PH Z.B
MOBKPWK7B#Q3I'Q \/R?$*]L=5GNM,NTOM;FN=.@A8L6F@5L;H58G:JC!8#-=
M+I=UXBU/X96&L6&M36O]AZK<Z8T<>L7%VU_=B>(I);2')GW!7C5'.T!R<\4
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M&]'_ * U=-Z5S&OP^7=^'8\YV7@_] :NG]*M;L]>7\.%^S_,DHHHJS(****
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M //Y!_WY/^-5VM]>_M"U==0MOLBD^?'Y)W.,<8.>*/D%_(VZ***905C>'O\
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MBB@ HHHH **** "L;P]_QZ7?_7Y-_P"A5LUC>'O^/2[_ .OR;_T*@#9HHHH
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MA_\ 7Y_[3:NB'6HCNS:I\,?1_F244459B%%%% !1110 4444 %%%% !1110
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MTH Z&BN>M]:U"[=DM+.RN&7[PBOE8CZX%6?MFO\ _0%B_P# H?X4 ;%%<_\
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M %%%% !1110 4444 %%%% !1110 4444 %8WA[_CTN_^OR;_ -"K9K&\/?\
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M+V:\#^&A=3J4DER-\@/4$]2*C6WTE+%K%8_"RVC-O: !0A;UQTS74_V+H_\
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M>T?^UTOOL=F$6(P>7Y*\L6S^=:7]BZ/_ - FS_[\+_A0 ?VUH_\ T%K/_O\
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MY/-;O]L:/@?\3:S_ ._Z_P"-4[KP_H\UY;3"SLXQ;L7=?)7D%2.:N_V+H_\
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M'(/S=C5J'1-'C@CC.F6;%5"Y\A><#Z5<AAAMXEAMX4AC7HB*% _ 4 6****
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M$O-.U#6;Z\T=M+DNG51&MP)8Y0N?WG4G<223GM@=JZ/7+::\\/ZA:0QO))-
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M@1,N%], %,CZF@#V9YH8PQDE1=N-VY@,9Z9IRR(Q*JX)&,@'.,]*\5O?A_\
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M+C\PR;5#D;=V.<>E2=1SR* /(M/\>:]=""W:XTC^T?MOE&V#!Q.C8($;JVW
M3)9NQP,<UZ]61_8.A_N?^)19_NF+Q_N%^1B<DCC@YK7H \B\3?%+4M,\3ZIH
M6F:7@VL*".:YC90TAD56?)PIC4-UR,GO7H6@ZC+JWANRU)G4RSQ!F**5!/?
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MN56(Y /<4EUI>G7P9;ZQM[E3C<)HE<''3J.U6HXHX8DBA18XT 5548  [ 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_s3aimg11.jpg
<TEXT>
begin 644 cvm_s3aimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %T B0# 2(  A$! Q$!_\0
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MH GHJ'S8]H;<,')!SUQ2B6,R&,2*7 R5SR!]* ):*** "BBB@ HHHH ****
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MNZ* /+_A?H^I> ?@S8V_BCS9;ZUCFO+BWM4:8P[W:3R8U7).T$* /3CBN?\
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MX=/T^&!K*WA+7<R *APF<YQEL9S@>M=]10!\_>%=%M/A_I?CC4M-T+7+_P
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M8EFW <==\?IF/P5U[1+/1[_5]1U*#[/:VUG:23L6WK\QV*0H7[W..G%>NT4
M?/7B^T\1:7X!\":3I,FH36.JWD;^(M5-A-<2N%ASB:)-LGELP"D#;A4"]#@\
MAXN\.:EX:M['P_IOAG7M2\/VVB:AJ\-LEHS_ &O59G*(9$C&R/8K&18^-N.!
MN%?6E% 'S%I7PQD\6>(O"?A?6=+U33_#F@^$8[>\9S) ]Q<3,-T88' )"DOC
MG#;3UXZ+P#H-S'\;=7U!=$O#H\\/]I1W.I6KPW.FW3 0FUWGB:,Q_,H!8)@=
M#U][HH **** "BBB@ HHHH **** "BBB@ HHHH *\M\17VI6?Q-CNF2*9;>.
M".PLY878S>8Q$KQL.%<< D]A[UZE28&0>] 'BMMIMG?:K;:7=0S17T$VH/K$
MRH5;RCDH6;&&!/EE1STK;\*W1TWQ,FGR:7<2->*6AFEX:*)@7SM P 3][&,$
M@8XKT_'7WI<#.>] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45#-,(83(P) QP.])YLW_/J?\ OH4 3T5!
MYT__ #ZG_OH4>=/_ ,^I_P"^A0!/14'FS?\ /J?^^A1YT_\ SZG_ +Z% $]%
M0>=/_P ^I_[Z%'G3_P#/J?\ OH4 3T5!YT__ #ZG_OH4>;-_SZG_ +Z% $]%
M0>=/_P ^I_[Z%)'/NF\EHRC;=W)SQ0!8HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #M24=JK37"P[=R
M2-DX^1"V/RJ6[*[&E<L_A157[4N^1/+DR@R3L.#]/6D^V+B(^3+^\.!\AX^O
MI4\R[CY66Z*J?;$S+^ZE_=]?D/S?3UH^V)F(>5+^\Z?(?E^OI1S+N%F7,453
M^V+ME;R9?W9P1L.3]/6E-VOF1IY<F7&0=AP/J>U'/'N'*RW15+[8GE/)Y,V$
M.TCRSD_0=ZH:AXBTC2;B"/4[H6K3J6C+J<-CKSCMD?G34HO1,EZ;FYFDKE?^
M$]\)^29/[57 ;;CRVS^6.E/_ .$X\*^;Y7]KQYV[L[6Q^>.M.XKG3T5E6NK6
M=]IL-_:&6:WF.$98VY[9QUQ5G[0OFO%Y<N47<3L.#]#W-'S*L7,48JG]M3RH
MY/)FPYP!Y9R/J.U.^U+OD3RY,H,D[#@_3UJ>>/<=F6L48JI]L3$1\F7]Z<#Y
M#\OU]*7[6G[W]S+^[Z_(?F^GK1SQ[A9EK%%5?M:?NOW,O[SI\A^7Z^E)]M39
M*WDS?NS@C8<GZ>M',NX69;XI:J?:E\R./RY,R#.=AP/J>U,^VIY3R>3-A#MQ
MY9R?H.]'/'N*Q=YI*JBX7SEB\N3YEW9V' ^I]:9]NC\@S>3/@-MV^6=WY>E'
M-%=1V9=I<55^T+YYB\N3(7=G8=OY^M1_;H_)$WDS8+;<>6=P_#THYHKJ%F7\
M452^TKYLD?ER91=Q.PX/T/<TGVV/RHY/)FPYP!Y9R/J.U'/'N'*R[69JFKZ;
MH\,4VIWL=JDTGE1ES]YL$X'O@$_A5K[4NZ1?+ES&,D[#@_3UK@OB9<'[%X:N
M([6ZE_XF7^KBA9Y/]1+_  CFFI1>B8K=SHI/%?AV]5;6UU6*6:1U5$ .2<CV
MKDI+K5H/B7<7CW4T.EQZC';23&<E%#0*1&8N@#,1\_8UA0:M-#<Q3?V+K;>6
MP;!T^7G'X5TC>/&=9%?P;JC"0@N#82?,1W/R\]!5)A8CN/&%])H<EKM%MYMA
M)-#*)2\K.I.1[8 []>U=)9^)I)O"-[KSVF?LV_%LI_>KMXQ(/X6[D=A7.?\
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M%% !1110 4444 %%%% !1110 5SGB+_D-^%_^PBW_I/-71US7B/_ )#?A?\
M["+?^D\U)@;^:7-1;J-U9FA+14>ZEW4 /HIFZC=0 ^BF;J-U 6),T9J/=2[J
M!6'YHS3-U&Z@"0'D5SO@SG1;EO[U_<G_ ,BM6^I^85@>"?\ D6BW]Z[N3_Y&
M>KB)G2T4451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<&BW'Q(T?Q0T]K+-Y&EV*+Y80J-SNLK[?O8 (Y_"O5: "BBB@ HHHH ****
M"BBB@ HHHH B[FN<U[_D8M'_ .N<_P#[3KH^YKG->_Y&+1_^N<__ +3JH?$8
MU?A^XYSX@:IIEMIMO:7DT9E$BS"UGCD,5R.5",RJ0#D@@'N!FD^',OVC0KB9
MKB-Y/.2*2&/>5@9(E4C+@')QDX&.:Z#7M-FU&R@-MJ'V"XM)UN(9F4,@89&'
M4]002/;K4>@Z?-9B]NKK4TU&\O9A-/+$ L:D*%"J 3@  =>36W4YY?"S9T;_
M )!*_P"_)_Z,:M6LK1O^02O^_)_Z,:M6L'\3.FG\*]$.HHHI&H4444 %%%%
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M ,@E?]^3_P!&-6I6+^)G33^&/HAU%%%(U"BBB@ HHHH **** "BBB@ HHHH
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MTK8KY_\ A>UO8_$MM-D\,>#=,O/+O;=VT.%UN87@E5") Q^5'!# XYXKZ H
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MX% 'M^1G&1GKBEKSKP1J$?V^73;O[6^HK$$S/SMCCP G7@C<"2>I)QTKT6@
MHHHH **** "BBB@ HHHH **** /$/C4VSQ)X>?UMKE?_ !Z.O,_/KT?X[-LU
M;PV_K'<K_P"@5Y)Y_O7V.51OAUZL^+S:5L0_1&IY]'GUE^?[T>?[UZGLSR><
MU//H\^LOS_>CS_>CV8<YJ>?1Y]9?G^]'G^]'LPYS4\^CSZR_/]Z//H]F'.:G
MGT>?69YU)Y_O1[,.<U//I()=WB+1A_T\/_Z*>LSS_>I;"3?XGT<?]-W_ /13
M5QXV%J,_0[<!.]>'J>C;J-U145\,?>DNZC=45% $NZC=45% $NZC=45% $NZ
MC=45% $NZC=46:7- "_>U#2U_O:C;#_R*M?0]?.\1_XF^B_]A.U_]&BOHB@
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M:_\ HP5]$5\\V8W>(=!7UU.W_P#0J^AJ "BBB@ HHHH **** "BBB@ HHHH
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_s3aimg10.jpg
<TEXT>
begin 644 cvm_s3aimg10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M *\HL?AW+:_#_3I_$D.L>(-7ATNSLUM+::&VET]8VCD/D%2@WI(BMN+$GRU
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M"L:D>6W RN]3N^;H*N7'C"2S\06]A<BT-MY<332I(=SAHW<RQCO&NSD^_MR
M=Q16%H>L0ZM"6:2!;Q.9[:.4.UODG:K^C8X/N".U;;,J(6;@"@!U5C(\QVP\
M+WD[?AZTW:]Q\TH*1?\ //NWU_PJT  , 8% $4<:QKM4=>23R2?>IJ*CDE6,
M#/+'HHZF@!S,JJ69@H'4FJW[Z8\92'UZ,W^ _6A8F9A)<8)'*H.B_P")JW0
MU55%"JH"CH!3J*IW-U;V=K)=7<Z001*7DED8*J =22>@H L]J\B^)'QFT?P:
MDNFZ7LU+7.GE YCMSZR$=_\ 9'/KBO/?B9\=IKLSZ'X+F:"#E)=0^Z\GJ(_[
MH_VNOICJ? W=I'9W8LS'))Y)->_@<JE.U2KMV_S/)Q.-M[M/[SL+KXG>/KJ[
MEN7\5:C&TC%BD5PR(N>P4$ #V%0_\+*\??\ 0X:M_P"!;_XUR=%?2?4Z/\J^
MY'E^WG_,SK/^%E>//^APU7_P*?\ QH_X61X^_P"ANU3_ ,"G_P :Y.BCZK1_
ME7W(GVL^[.L_X65X\_Z'#5?_  *?_&C_ (65X\_Z'#5?_ I_\:Y.FNZHNYCB
MCZK1_E7W(/:S[LZ[_A97CS'_ ".&K?\ @6_^-6M!^)7CBZ\5Z3:OXLU22&6\
MB1PUTY# N 1C/2O.Y9FD..B^E:?A7_D<]$_Z_H?_ $8*\O$4*2B[17W([:=2
M=U=L_1OM12+]T4M?('OC:S](_P"08/\ ?D_]#:M"J&D@KIJA@0=\G!_WVI]&
M3U-&BBBD4%%%% !1110!!=_\><__ %S;^51V/_(,M?\ KDG\A4EW_P ><_\
MUS;^51V/_(,M?^N2?R%/H3U(8?\ D-WW_7.+_P!GK0JA!_R&[[_KG%_[/5^I
M8T+1113&%%%% !1110 4444 %%%% !1110 4444 %8^N6/\ :FDRZ:UP\$5Q
MA96C^\T>1N3/;<,KGWK8HH P]2TW4+J".#3-6_LR((8V1;=) 5(P,9^Z1VZC
MU!J-M!LUT;3M)B9DM+(11X(#-)''C"$^A*KGUQCO7044 <MH_AF/1]3GOOMD
MEQN1HH49 OE(TC2$$C[QW,>3V_$GJ:** "BFLRJI9B !U)JKF2?[N8XO[W1F
M^GH* '/*23'" SCJ3]U?K_A4D<*QY;.YS]YSU-/1%C0*BA5'84^@ HIDDB1K
MN=L#^=0;7G&9ALC[1]S]?\* &^?N4^7$\J_WEQ@_3)YKR'X_32'P;80E)(XY
M+T!U)&&PC$9 //->T=Z\;_: _P"1.TW_ *_A_P"BVKMR_7$0OW.3&?P9'S1]
MEM_^>"?]\TA@M5^]#&/J!4U:_AWQ1KGA^62STS0=,UB6]F18DO;?S7WGY55.
M1C)-??8F?L:;E&-_P/DZ<>>5F[&"(+1ONQ1'Z 4>1:$X$41/I@5ZW\6KZUT^
MRT#0?[+TT:Y%Y=[J)LX5BC!Q_JAC)P<GKV />KW@?Q%'XRL_$3>*O!^BZ?X7
ML;4LMS;P;#')_=#GJVWG(P0<>M>9_:;5.,_9Z/S\[:=SK^JW;7/JCQ<V]JOW
MH8Q]0*#;VH&3#&!]*]1^',-Q>>#[:Y\.Z79ZCJC:XD.J"YCC=XK'UP_W5QSD
M=\U<A\.V<.O:_J'A^UM[Q]2O)-+T"W8*T60-UQ.,\;(\, >1P1W%0\V@IN,H
M[?UJ"PDW%2ON>1_9K?\ YX)_WS7,ZPJIJ;*BA5"KP.G2O2]>\)ZAX=L[6^EN
M[+4+&Y=HH[JQG\Z,R+PR$X&",'\C7FVM?\A9QU.U?Y5VU:U.=!5*;NKDTH25
M3D9FUN^&;6Z76K+5$C'DVDZ39;@.58' _*IM+\/%]MQJ"E5ZK#W/U_PKIU55
M4*JA5'  X K\\SK.H4KTJ+YI=7T7IW9]_E.23JVJUE:/1=7Z]D>S_P#"^K__
M *%V'_O^W^%'_"^-0_Z%Z'_O^W^%>,T5\%_:U;^;\$?9_P!CX?\ D_%GL_\
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M2=2GO;43%Y04422%EB0N7*H.P+,3_P#6 KHJ *BQ-(P>?MRL8Z#Z^IJW110
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M_L^?\E"NO^P>_P#Z,CKZ# ?[Q'U/FLQ_@2]#ZAQ=?\](O^^#_C1BZ_YZ1?\
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M=JZG_A'[#_GI-^8H_P"$?L/^>DWYBOT*C0IT(\L$?FU?$5*\N:;N<M175?\
M"/6'_/2;\Q1_PCUA_P ])OS%;F!RM%=5_P (]8?\])OS%'_"/6'_ #TF_,4
M<K2R-%;Q^9<-@=E'5JV=8TZVTO2WO;<N[JP4!^G-<3++)-(9)&+,>YH FNKR
M6Z.#\D8Z(.E?4OP=A#_"G2V\R1?GFX5L#_6M7RC7UI\&O^23Z5_OS?\ HUJ
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MVQ\*9T%KX=TWP59^*O$DUX;:^F\F&.S R@R1N8G_ '2?RJ]<>%8(/'MEX?\
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MN$N;2"P@DN!NMX%*^>SA6*X8%P>I("^U=)KFDW6K?9%M[Y;3[--YQ1X!*DC
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M]JM_^>GZ&@![*VTA2 >V:\U\:_#&X\=I'%JNO/%%%)YB+%'T.,=Z]'^U6_\
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M-I(1<0SD2R"4[I ['.[<WS'OGD8K7DTFR^PV-@L9CMK22,Q1(<+^[^X#Z@$
MX]0*** *NEZ!IVE:E<W=KYQD?,:K)(66%"QD*H.P+,3^78"NBHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
